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Este projeto propõe-se promover o envolvimento dos 
farmacêuticos de farmácia comunitária em investigação 
clínica. Nos últimos anos, a profissão farmacêutica tem 
passado por vários desafios. Ao mesmo tempo, os 
farmacêuticos têm procurado desenvolver um papel 
mais interventivo na comunidade. As competências que 
os farmacêuticos têm permitem-lhes um papel mais 
interventivo em investigação clínica, quer cooperando 
com as unidades de saúde, quer como investigadores. A 
proximidade ao utente e a inserção na comunidade, 
permite às farmácias comunitárias terem um papel 
importante em investigação clínica. A realidade 
portuguesa, até ao momento, não parece acompanhar a 
realidade doutros países neste âmbito. No entanto, 
Portugal reúne as condições necessárias para que essa 
realidade se altere. A crescente importância dos dados 
de vida real e o posicionamento das farmácias na 
comunidade deixam espaço para que a sua intervenção 
em investigação clínica possa ser melhorada. Assim, 
num futuro próximo será importante que as farmácias 
comunitárias sejam chamadas para esta realidade. Este 
projeto sugere a aplicação futura de um questionário de 
modo a avaliar a sua exequibilidade, avaliando o 
interesse das farmácias comunitárias portuguesas em 
investigação clínica e as possíveis barreiras à sua 
participação. 
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abstract This project aims to promote the involvement of 
community pharmacists in clinical research. In the last 
years, the pharmaceutical profession has gone through 
various challenges. At the same time, pharmacists 
have sought to develop a more active role in the 
community. The skills that pharmacists have allow 
them a more active role in clinical research, either 
cooperating with health units, either as researchers. 
The proximity to the patient and the placing in the 
community, allows community pharmacies to have an 
important role in the disclosure of clinical research. The 
Portuguese reality, so far, does not seem to reflect the 
reality of other countries in this field. However, Portugal 
has the necessary conditions for this situation to 
change. The growing importance of real world data and 
the placement of pharmacies in the community leave 
space for its involvement in clinical research to be 
improved. Thus, in the near future it would be important 
that community pharmacies are called upon to this 
reality. This project suggests the application of a 
questionnaire to Portuguese community pharmacies  in 
order to assess the feasibility of this project, evaluating 
their interest in clinical research and identifying the 
possible barriers to their participation. 
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1. INTRODUCTION  
 
 
Over the years, the profession of Pharmacy has begun to undertake major changes in 
practice. Driven by marketplace realities the profession has recognized the need to 
provide cognitive services either than the traditional role of product supply which has 
made pharmacists feel their skills as underused (1, 2). 
The increased personal interest in these issues and the development of competences on 
clinical research during the curricular period of the Master course in Pharmaceutical 
Medicine led to develop the hypothesis of integrating both worlds.  
The current paradigm of Portuguese healthcare and particularly the changes faced on the 
Community Pharmacy setting make it possible to understand recent initiatives of 
extending community pharmacists’ role within this framework (2, 3). In order to increase 
pharmacist’s interest in research and promote their involvement, there is a need to fully 
investigate the barriers and facilitators to this new role (1). 
This project aims to show the international reality on this issue, in order to be the basis of 
further studies. It is intended that this work can be used as a guide and a facilitator for 
introducing clinical research, and clinical trials particularly, in the context of Portuguese 
community pharmacies. 
 
 
1.1. OBJECTIVES 
 
The information about clinical trials in a community pharmacy setting is limited in a global 
perspective and very scars when talking about the Portuguese reality. In an attempt to 
help fulfilling this gap the objective of this project is to identify the role pharmacists have 
and/or might have in clinical research; particularly, the potential role of community 
pharmacies in clinical trials.  
A global revision on this subject will be presented in order to help to delineate a possible 
strategy that can help to enhance the role of Portuguese community pharmacies in clinical 
research in the future. 
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1.1.1. METHODS 
 
This work consists in a review of international peer-reviewed literature on scientific 
databases ISI Web of Knowledge and PubMed using MeSH (Medical Subject Headings) 
and DeCS (Health Sciences Descriptors) terms “community pharmacies”, “clinical trial” 
and “clinical research”. Other main search term used was “pharmacist” due to its 
relevance for this study. The search was focused in publications of the last five years, 
although some older publications were also used due to its relevance for the study or 
because it is a primary source which should be cited. Clinicaltrials.gov and 
clinicaltrialsregister.eu were also consulted in order to find clinical studies in community 
pharmacies. The search was extended for English and Portuguese manuscripts, because 
it is the language of proficiency of the research team and of the target population.  
Reference lists of retrieved studies were reviewed for relevant articles. Studies were 
assessed for relevance based on the abstracts. Relevance was judged by health 
improvement and the role of community pharmacy and community pharmacists, 
particularly. Manuscripts in which community pharmacy or community pharmacist were 
not a major heading were excluded.  
Grey literature such as conference proceeding, abstracts, presentations and technical 
reports were identified on these topic using generic search engines (e.g. Google). 
The findings are presented as a narrative summary. 
 
1.1.2. STRUCTURE 
 
To answer the issue in debate, it was necessary to verify the current situation (state of the 
art) of clinical research, particularly of clinical trials.  
In attempt to positioning the community pharmacy in clinical research, it is described what 
has been done on this subject and in chapter 4 some real-life examples are shown. 
In chapter 5 it was tried to transpose this kind of research to Portuguese reality and a brief 
description of the involved stakeholders is made. Then a suggestion is given: a 
questionnaire to be filled out by Portuguese pharmacies. This questionnaire lacks 
translation and validation to the Portuguese population; therefore, in this chapter 
Strengths, Weaknesses, Opportunities and Threats (SWOT) of its application are 
analysed. 
In chapter 7, all data obtained are discussed and finally, in chapter 8 a conclusion of this 
project is presented. 
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2. CLINICAL RESEARCH OVERVIEW  
 
 
Clinical research is research that directly involves a particular person, or group of 
individuals, or that uses materials from humans, such as their behaviour or tissue 
samples. Clinical trial defines a particular case of clinical research. It is any investigation 
in human subjects intended to discover or verify the clinical, pharmacological, 
pharmacokinetic or pharmacodynamic effects of an investigational medicinal product 
(IMP), or to identify any adverse reactions to an investigational medicinal product, with the 
objective of determine its safety and/or efficacy. (4, 5) Figure 1 shows several types of 
medical research.  
 
Figure 1. Classification of different study types (adapted from (5)). 
 
 
2.1. CLINICAL TRIALS - CONTEXT 
 
It may never be known for certain who carried out the first controlled clinical trial. 
According to the written history, James Lind is considered the “father” of modern clinical 
trials, since he was the first one to conduct a recorded controlled clinical trial, in 1947. In 
1753, he published his account of a trial of six potential remedies for scurvy. He allocated 
two scorbutic sailors to each treatment: cider, sulphuric acid, vinegar, seawater, nutmeg 
paste with barley water, or citrus fruit (two oranges and one lemon), once daily. This was 
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Quality 
Efficacy Safety 
an open trial, had no placebo arm, used only 12 patients and it cost almost nothing; yet it 
led to profound and permanent changes in clinical practice and in health of countless 
people (6). About 50 years later came what might be the first placebo-controlled double-
blind clinical trial (7). 
Medicines were not subjected to systematic trial until the 20th century, even though 
powerful and effective preparations had by then been in use for millennia (7). 
The first large-scale randomised controlled clinical trial is generally recognised to be the 
United Kingdom (UK) Medical Research Council’s comparison of streptomycin plus bed 
rest with bed rest alone, in the treatment of pulmonary tuberculosis (8, 7). This trial which 
began recruiting patients in 1947 and whose results were published in 1948 became a 
landmark in the development of clinical trial methodology, because of its inclusion of a 
“best existing treatment” control group, its carefully organisation and its use of sealed 
randomisation envelopes (7). 
These characteristics (use of control groups, randomisation and blinding) have become 
essential for the results of an interventional clinical study to be realistic. 
In this way, 1990 is also a milestone in the history of clinical research. The International 
Conference on Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use (ICH) was assembled to help eliminate differences in 
drug development requirements for the three global pharmaceutical markets: European 
Union (EU), United States of America (USA) and Japan. The birth of ICH took place at a 
meeting in April 1990, hosted by European Federation of Pharmaceutical Industries and 
Associations (EFPIA) in Brussels. Representatives of the regulatory agencies and industry 
associations of Europe, USA and Japan met primarily to plan an International Conference. 
However, in this meeting wider implications and terms of reference of ICH were also 
discussed. The ICH initiatives promote increased efficiency in the development of new 
drugs, improving their availability to patients (9). 
ICH stands Good Clinical Practice (GCP) guidelines whose principles represent agreed 
scientific guidance for meeting technical registration within the three ICH regions. The ICH 
Guidelines are not intended to be comprehensive guidance covering all aspects of product 
development and registration. Instead of this, they are intended to be used in combination 
with any regional requirements (9). Thus, ICH Guidelines objective is to standardize the 
conduction of clinical trials in accordance with GCP. 
In the end of the day, ICH GCP Guidelines seek the development of drugs with Quality, 
Safety and Efficacy (cf. Figure 2).  
 
 
 
Figure 2. Standards in Clinical Development. 
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2.2. CLINICAL TRIALS KEY STAKEHOLDERS 
 
The complexity of clinical trials associated to research and development of new 
medicines, implies the involvement of several stakeholders as described below (7, 10). 
 
Figure 3. Clinical Trials’ Stakeholders (adapted from (10)).  
 
Sponsors are generally pharmaceutical companies or academic institutions that are 
responsible for the conception, performance, and management or funding of clinical trials. 
Sometimes, these activities are subcontracted to Clinical Research Organisations (CROs) 
(7, 10). 
Clinical sites are healthcare organisations (public or private funding), laboratories or other 
entities that gather the needed conditions (technical and human resources) to perform 
clinical trials. Nowadays, hospitals comprise the majority of the clinical trial sites and in 
this way, hospital administrations are also considered to be an important stakeholder in 
what concerns clinical trials (7, 10). Nevertheless, other clinical trial sites begin also to be 
recognised. 
CROs may have several roles in clinical research since they may ensure all research 
activities or only a few ones (depending upon the scope of their individual work). There 
are several CROs around the world. Some of them are specialized in some areas of 
clinical research as clinical monitoring, data management, regulatory activities, 
pharmacovigilance, etc. 
The clinical team is led by a principal investigator (usually a physician) who is responsible 
for the clinical trial at the site and clinical team coordination. This clinical team may include 
several figures since sub-investigators, study nurses, pharmacists, study coordinators, 
Sponsors 
Clinical Sites 
CROs 
Research 
Teams 
Regulatory 
Authorities 
Patients 
Hospital 
Administrations 
Stakeholders 
CROs: Clinical Research Organisations 
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etc. (7, 10). Each one of them has a specific role among the clinical trial which is specified 
in the protocol and assigned in the delegation log. 
Clinical trials may vary in size, and consequently can involve only a single research entity 
in one country, or multiple entities in multiple countries. 
Regulatory Authorities are all those which regulate the pharmaceutical sector (10). Food 
and Drug Administration (FDA) and European Medicines Agency (EMA) are examples of 
regulatory authorities. In each country Local Authorities such as Infarmed (Autoridade 
Nacional do Medicamento e Produtos de Saúde, I.P. – National Authority of Medicines 
and Health Products, in Engli), Ethics Committees as CEIC (Comissão de Ética para a 
Investigação Clínica – Ethics Committee for Clinical Research) and CES (Comissão de 
Ética para a Saúde – Ethics Committee for Health) and CNPD (Comissão Nacional de 
Proteção de Dados – National Committee for Data Protection) for Portugal have an 
important role in the country’s Clinical Research environment.  
Patients are the central stakeholder in this scenario since they are the reason for clinical 
development. Depending on product type and development stage, investigators enrol 
volunteers first (Phase I), then patients into small pilot studies, and subsequently conduct 
progressively larger scale comparative studies. As positive safety and efficacy data are 
gathered, the number of patients typically increases.  
All these stakeholders interact with each other in several ways. For instance, regulatory 
authorities assess the clinical trial application (CTA), as well as supervise its 
implementation and conduction. Sponsors contract a CRO to conduct, total or partially, 
the clinical trials. The clinical sites, sponsors and CROs contract investigators, and other 
technical and administrative staff. The research team identify and enrol patients that fulfil 
the criteria and accept to participate in the study (10). 
All these interactions generate tax revenues to the Government (direct and indirectly). 
Moreover, additional revenues are generated from the development of new medicines 
(10).  
 
 
2.3. CLINICAL TRIALS CLASSIFICATION  
 
Clinical trials may be classified according to its purpose. The United States National 
Institutes of Health organises clinical trials into the following different types: 
 Prevention trials – to look for better ways to prevent disease in people who have 
never had the disease, or to prevent a disease from returning. These may include 
medicines, vitamins, vaccines, minerals, or lifestyle changes. 
 Screening trials – to test the best way to detect certain diseases or health 
conditions. 
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 Diagnostic trials – to find better tests or procedures for diagnosing a particular 
disease or condition. 
 Treatment trials – to test experimental treatments, new combinations of drugs, or 
new approaches to surgery or radiation therapy. 
 Quality of life trials – to explore ways to improve comfort and quality of life of 
individuals with chronic diseases. These are supportive care trials. 
 Compassionate use trials – to provide partially tested, unapproved therapeutics to 
a small number of patients who have no other realistic options. Usually, this 
involves a disease for which no effective therapy has been approved yet, or a 
patient who has already failed all standard treatments and whose health is too 
compromised to qualify for participation in randomised clinical trials. Usually, case-
by-case approval must be granted by both the FDA and the pharmaceutical 
company for such exceptions. 
Other clinical trials’ classification is related to whether the trial design allows changes 
based on data accumulated during the trial: 
 Fixed trials consider existing data only during trial’s design. In these kind of trials, 
they are not modified after beginning and do not assess the results until the study 
is complete. 
 Adaptive clinical trials use existing data to design the trial, and then use interim 
results to modify the trial as it proceeds. Modifications include dosage, sample 
size, drug undergoing trial, patient selection criteria and "cocktail" mix. Adaptive 
trials often employ a Bayesian experimental design to assess trial's progress. In 
some cases, trials have become an ongoing process that regularly adds and drops 
therapies and patient groups as more information is gained. The aim is to sooner 
identify drugs that have a therapeutic effect and patient populations for whom the 
drug is appropriate. 
 
 
2.4. CLINICAL TRIALS PHASES 
 
Clinical drug development involving new drugs are commonly classified into four phases. 
The drug development process will normally proceed through all four phases over several 
years. As said before, in a classic approach, the results from each phase determine the 
design of the next. The successful surpass through these phases will usually lead to the 
approval by the regulatory authority of a Marketing Authorisation (MA) of a new medicine 
(7). 
Table 1 shows a classification of clinical trials by type and purpose (9, 7). 
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Table 1. A classification of clinical trials by type and purpose (adapted from (7)). 
Phase Trial Type Trial Purpose Examples 
I Human pharmacology Assess tolerability Dose tolerability trials 
  Define PK and PD Single and multiple dose PK and/or PD 
trials – some in special patient groups 
  Explore drug metabolism and drug 
interactions 
Drug-drug interaction trials 
  Estimate activity  
II Therapeutic 
exploratory 
Explore use for the targeted indication Earliest trials of short duration in 
narrowly defined, subject populations, 
using biomarkers or surrogate endpoints 
  Estimate dosage for subsequent trials Dose-response exploration trials 
  Provide basis for confirmatory trial 
design, endpoints and methods 
 
III Therapeutic 
Confirmatory 
Demonstrate/confirm efficacy Large, controlled trials to establish 
efficacy 
  Establish safety profile Randomised parallel dose-response 
trials 
  Provide an adequate basis for assessing 
the benefit: risk relationship to support 
licensing 
Clinical safety trials 
  Establish dose-response relationship Trials of mortality/morbidity outcomes 
   Large simple trials 
   Comparative trials 
IV Therapeutic use Refine understanding of benefit-risk 
relationship in general or special 
populations and/or environments 
Comparative effectiveness trials 
  Identify less common adverse reactions Studies of mortality/morbidity outcomes 
  Refine dosing recommendations Trials of additional endpoints 
   Large simple trials 
   Pharmacoeconomic studies 
 
Phase I (screening for safety): this “first-in-human” phase intends to answer questions as 
“Is it bioavailable? Is it tolerated? Does it do anything that might be therapeutically 
useful?” In this phase, also known as clinical pharmacology, a small number (dozens) of 
healthy volunteers are subject to trials that intend to assess tolerability, safety, 
pharmacokinetics and pharmacodynamics – in case a biomarker or surrogate endpoint is 
available.  
Phase II (establishing the efficacy of the drug - usually against placebo): this phase 
intends to answer the question “Does it seems to work?” It can be subdivided into two 
subphases: Phase IIa and Phase IIb. Phase IIa trials are about clinical pharmacology in 
patients with the target disease (small number of patients: 10-200) to assess 
pharmacodynamics, pharmacokinetics, and dose-response relationships. Phase IIb trials 
PK: Pharmacokinetics  PD: Pharmacodynamics 
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relate to larger trials in several hundred patients to formally assess the dose-response 
relationship and increase understanding of efficacy, safety and tolerability.  
Phase III (final confirmation of safety and efficacy): these trials intend to answer the 
question “How well does it work?”. In this phase there are formal randomised controlled 
therapeutic trials (in hundreds or thousands of patients) to test efficacy and safety of two 
or more dose levels, and to compare new drug with existing ones. Usually this phase 
involves a multicentre international programme. 
Phase IV (studies during sales): this phase is about to “Look how well it works”. These are 
post-licensing studies in the target population, with wide entry criteria, to broaden 
experience in clinical practice. The objectives of this phase are typically surveillance for 
safety, or further comparisons with other therapy. The results are more likely to be used 
for marketing purposes than in support of applications to regulatory authorities.  
As can be noted, each phase has a different purpose and helps the investigator to answer 
different questions. However, in addition, it should be noted that before the conduction of 
clinical trials, pharmaceutical companies conduct extensive preclinical studies (also known 
as non-clinical studies) as described in Figure 4. 
 
 
Figure 4. Clinical Trials’ phases in the development of new medicines  (adapted from (10)). 
 
 
2.5. OTHER TYPES OF CLINICAL RESEARCH STUDIES 
 
Randomised clinical trials are an essential part of drug development, but they do not 
provide all information needed to know a medicine (7).  
Clinical research types’ classification is guided by researcher’s behaviour. In this way, 
clinical studies include both interventional (or experimental) studies and non-interventional 
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(or observational) studies. In an observational study, the investigator observes the 
subjects and measures the desired outcomes and does not actively manage the study. In 
the other hand, in an interventional study the investigator gives the research subjects a 
particular medicine or other intervention. A clinical trial is an interventional clinical study. 
Interventional studies may also include those on medical devices and in which surgical, 
physical or psychotherapeutic procedures are examined. Usually, investigators compare 
the treated subjects to subjects who receive no treatment or standard treatment. 
Subsequently, researchers measure subjects' health changes (5, 7). 
In contrast to clinical studies, non-interventional studies are those in the context of which 
knowledge from the treatment of persons with drugs in accordance with the instructions 
for use specified in their registration is analyzed using epidemiological methods. The 
diagnosis, treatment and monitoring may be performed according to a previously specified 
study protocol or exclusively according to medical practice (5, 7). 
In an observational study, investigators assess health outcomes in groups of participants 
according to a protocol or research plan. Participants may receive interventions, which 
can include medical products, such as drugs or devices, or procedures as part of their 
routine medical care, but participants are not assigned to specific interventions by the 
investigator (as in a clinical trial). For example, investigators may observe a group of older 
adults to learn more about the effects of different lifestyles on cardiac health.   
According to Figure 1 there are several types of clinical research studies beyond clinical 
trials. All of them give their input and have a great impact in the development of medicines 
and healthcare knowledge. 
 
 
2.6. NEW DRUG DEVELOPMENT 
 
As said before, clinical trials are only a small part of the required research to develop a 
new treatment. First, there are several laboratorial tests, from discovering, purifying, 
characterizing and test (in cell and animals). These types of tests are required before 
conducting clinical trials. In fact, about 1000 potential drugs are tested just before the 
point of being tested in clinical trials is reached (7). 
Nevertheless, the time taken to complete clinical trials continues to be the major holdup in 
drug development. On average, about eight years pass from the time a medicine enters 
into clinical trials until it receives approval from regulatory authorities for marketing (7, 10). 
Figure 5 demonstrates the cumulative approvals for medicines by FDA in the period 1990 
– 2011. New medicines include New Drug Applications (NDAs) and Biologics License 
Applications (BLAs) (11).  
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Figure 5. Cumulative Approvals for Medicines in USA (1990-2011) (adapted from (11)). 
 
There are several reasons that lead a clinical trial to last several years. First of all, only 
certain people who have the target disease condition are eligible to take part of a specific 
clinical trial. On the other hand, researchers who treat these particular patients must 
participate in the trial. Then they shall identify the desirable patients and obtain consent 
from them to take part in the trial.  
In certain cases, clinical trials not involving a new drug might have, a much shorter 
duration. Nevertheless, epidemiological studies are exceptions for this situation. 
Nowadays, the level of activity in the pharmaceutical industry’s pipeline implies new 
challenges. Clinical trials are requiring more and more data (which often means more 
patients) which obviously means more resources. Moreover, real world data is recognised 
to have much more importance nowadays. This field could also be improved with the 
conduction of other clinical studies besides clinical trials. 
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3. CLINICAL RESEARCH IN THE CONTEXT OF COMMUNITY 
PHARMACY  
 
 
3.1. PHARMACISTS: SCOPE OF WORK 
 
Pharmacists have competencies to work in various fields, including community 
pharmacies, hospitals, pharmaceutical industry (development, manufacturing, quality 
control, marketing and regulatory affairs), medicines’ wholesale distribution, clinical 
analysis and various other analytical activities (chemical, hydrological, microbiological, 
toxicological, etc.), teaching and research. To practice pharmacy, in Portugal, generally, a 
pharmacist must register to the Portuguese Pharmaceutical Society, known as “Ordem 
dos Farmacêuticos” (OF). Although not applicable to all pharmaceutical activity areas, this 
is a mandatory requirement to work in community pharmacy. 
Pharmacists’ mission is to improve public health by ensuring safe, effective, and 
appropriate use of medications (12). Many pharmacists, however, felt unsatisfied with 
their predominant dispensing role and thought that a closer work with patients would make 
their work more interesting (2). So, over time they have already become more in contact 
with patients by measuring blood pressure, serum cholesterol and glucose concentration 
(13, 14). Contemporary pharmacy practice reflects an evolving paradigm from one in 
which the pharmacist primarily supervises medication distribution and advises patients, to 
a more expanded and team-based clinical role providing patient-centred medication 
therapy management, health improvement, and disease prevention services (12, 14). 
Nowadays, trained pharmacists should be able to develop new skills (13, 14).  
Nowadays, pharmacists have extended roles in the community. They have moving from 
prescription provider to pharmaceutical care provider (1, 3, 15-17, 14). Nevertheless, 
pharmacists continue arguing for increased scope of practice (1, 18). Pharmacists’ 
professional role expansion has been based on the assumption that they have key roles 
to play within the healthcare system. However, there are relatively few studies to support 
this assumption (19, 3). The “Practice of Pharmacy” means interpretation, evaluation, and 
implementation of medical orders; participation in drug regimen review; drug or drug-
related research; patient counselling and all those acts or services necessary to provide 
pharmacist care in all areas of patient care, including primary care and collaborative 
pharmacy practice; and the responsibility for compounding and labelling of drugs and 
devices, proper and safe storage of drugs and devices and maintenance of required 
records. Pharmacy practice also includes continually optimizing patient safety and quality 
of services through effective use of emerging technologies (12).  
Community pharmacies are considered to be the first point of contact in the healthcare 
system since they are integrated in community and easy accessed by the population (15, 
20). Community pharmacies are the most easy and common way of contact that patients 
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have with primary healthcare services (20). In this way, today, pharmacists offer a range 
of services to the community, such as patient education and counselling, medication and 
lifestyle management, health promotion, screening, prevention and management of 
chronic diseases (21, 22, 3, 23).  
In New Zealand, all pharmacies inquired by Tordoff et al. provide some baseline services 
(advice, dispensing of prescriptions, medicines disposal) and 90% provide home delivery 
of medicines. 35% of the enquired pharmacists provide screening (e.g. cholesterol, blood 
pressure), and 32% provide medicines education to community groups (23).  
In Portugal, the establishment of pharmacies is determined by demographic and 
geographic criteria. In 2010, there was one pharmacy for every 3725 citizens. This 
prevents pharmacies from being concentrated in central urban areas and promotes a 
more homogeneous distribution throughout the country. Portuguese pharmacies are 
usually small companies, with an average of 5.7 employees (24, 15). Portuguese 
pharmacies and their pharmacists actively promote healthy lifestyles and prevention of 
illness, which makes Portuguese pharmacies a place for healthcare and promoting 
community’s well-being. In fact, the pharmacist plays an active role in promoting the 
rational use of medicines, pharmacovigilance, health education, disease detection, and in 
providing medication related information. Besides the regular dispensing role, Portuguese 
community pharmacists are involved in disease management programmes for diabetes, 
hypertension and asthma (15). Table 2 shows the ranking of the services provided in the 
Portuguese community pharmacies (25). 
 
Table 2. Ranking of Pharmaceutical Services (Associação Nacional das Farmácias (ANF) - 2010) (adapted from (25)). 
Ranking of Pharmaceutical Services 
1 Checksaude – Total Cholesterol 
2 Checksaude – Blood Pressure 
3 Checksaude – Glycaemia 
4 Checksaude – Triglycerides 
5 Checksaude – Weight 
6 Drugs Administration – Miscellaneous 
7 Checksaude – Pregnancy 
8 Diagnostic and Therapeutic aids – Nutrition and Dietetics 
9 Checksaude – BMI + Waist Circumference 
10 Checksaude – Uric Acid 
11 Checksaude – BMI 
12 Drugs Administration – Vaccines 
13 Checksaude – HDL Cholesterol 
14 Checksaude – Lipid Profile 
15 Checksaude – Haemoglobin 
16 Checksaude – PSA 
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17 Diagnostic and Therapeutic aids – Podology 
18 Checksaude – FVC 
19 Checksaude – INR 
20 Pharmaceutical Care Program – Diabetes 
 
 
3.2. PHARMACISTS’ ROLE IN CLINICAL RESEARCH 
 
The increasing number of clinical trials worldwide has opened a range of new 
opportunities for those wishing to work in the clinical research field. The design, 
coordination and analysis of a clinical trial require a multidisciplinary team: principal and 
sub-investigators, clinical research coordinators (CRC), research pharmacists, clinical 
research associates (CRA), and many others (26). 
Pharmacists can play an important role in the way clinical trials are conducted and may 
contribute in several ways in the research process. They can use their expertise and 
collaborate directly on pharmaceutical issues such as drug composition and management 
of indications, dosage, administration, contraindications, adverse effects and interactions 
of the investigational medicinal product (IMP). Pharmacists can also help to ensure the 
safety of human subjects and the protection of their rights. For instance this can be done 
through the participation in local Institutional Review Boards (IRBs) or Independent Ethics 
Committees (IECs) (26). 
The accurate control and management of an IMP is an important issue to the success of a 
clinical study. Pharmacist, as the drug specialist, is the most suitable team member for 
this task (26). 
Pharmacist role in clinical studies includes ensuring that the drug receipt is recorded in the 
study documents or in the interactive voice (or web) response system (IVRS/IWRS). 
Pharmacist has also the primary responsibility of drug dispensing. They should only 
dispense an adequate amount of IMP to each subject and this amount should cover dose 
requirements until the next visit. It is important that patients are aware of the need to 
return all unused medication. It is pharmacists’ duty to verify the medicinal product 
packaging and labelling, the drug substance analysis, pharmaceutical form, batch 
number, manufacturing and expiration dates, the correct use, handling and storage 
conditions (temperature, light and humidity), the drug administration routes and specific 
dosage. Pharmacists should also be aware of all dispensing, incinerating and handling 
procedures in case of chemotherapy drugs. In the end of the day, pharmacists should 
ensure that the IMP is in good condition for use. All the conditions described above are 
determined and stated by the sponsor and all data should be completely recorded (26).  
During IMP’s receipt and shipment, the pharmacist should ensure that the transportation 
is performed according to the instructions specified by the sponsor. If there are any 
questions regarding the quality or physical aspects of the IMP, the pharmacist should not 
BMI: Body Mass Index    FVC: Force Vital Capacity 
HDL: High-Density lipoprotein   INR: International Normalized Ratio 
PSA: Prostate-Specific Antigen 
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distribute the drug and must immediately contact the sponsor (26, 27). Given the above, 
pharmacists must be familiar with the clinical trial protocol (CTP), informed consent form 
(ICF), investigator’s brochure (IB), and standard operational procedures (SOPs) of the 
research site, which include regulatory, ethical, and legal requirements. 
Instead of working specifically as a pharmacist in research projects, pharmacists may 
rather work as CRC (Clinical Research Coordinator). The CRC’s role is assisting the 
investigator to comply with the research project requirements, aiming to obtain reliable 
trial results and to ensure the well-being of subjects involved in the study (26, 28, 29). 
Data quality is required to guarantee that study data is reliable and complete in order to 
accurately assess the safety and effectiveness of medicinal products. The accuracy of 
data entry is verified by a CRA (Clinical Research Associate) who is also responsible for 
evaluating whether the clinical study is being conducted according to the ICH GCP and 
applicable requirements. All clinical studies require continuous data and safety monitoring, 
which is sent to the sponsor. The monitoring visits enable the CRA to act as a link 
between the sponsor and the research site. Pharmacists have competencies that enable 
them to perform this role perfectly (26).  
At this time, pharmacists are at the forefront of patient care and have a significant impact 
on patients’ management. Moreover, the pharmacist may play a central role in the 
research process, which can influence directly the success of a clinical trial (26). To 
participate in clinical research, pharmacists would also need adequate facilities, a strong 
professional motivation and a good relationship with the public and local physicians (13). 
There are few pharmacists practicing in institutional settings and most people who benefit 
from pharmacy services are in the community. Thus, evidence of the impact of 
pharmacists’ interventions in community settings must be generated (19). Moreover, most 
pharmacists in community practice have had limited exposure to clinical research 
methodology (19). Academic researchers’ skills may lead them to design rigorous 
experimental studies, but taking that research to the field requires active participation of 
pharmacy professionals. 
 
 
3.3. PRACTICE-BASED RESEARCH 
 
The concept of using community pharmacies for practice-based research is relatively new. 
Little is known about community pharmacists’ willingness to participate in community-
based research and the perceived barriers to participation (30). Figure 6 intends to 
illustrate the importance of practice-based research for translating research into practice 
and into materials for patients (31, 32). 
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Figure 6. The importance of practice-based research for translating research into practice (adapted from (31)). 
 
Kosta et al., aim to explore how pharmacists involved in the Pharmacy Study Of Natural 
Health Product Adverse Reactions (SONAR) project perceived the barriers and facilitators 
to participate in clinical research (33). Also Peterson et al. aim to conduct an Australian 
national cross-sectional survey of randomly selected Australian pharmacists to determine 
their attitudes towards the involvement in pharmacy practice research. Survey questions 
assessed attitudes to research, involvement in research, barriers and facilitators to 
involvement, self-assessed understanding of research terminology, and access to and use 
of electronic bibliographic databases (34). 
Previous studies of pharmacy-based clinical research participation focused on estimating 
how many pharmacists were willing to participate in research without attempting to fully 
understand why (33). Three studies in the United Kingdom reported that the percentage of 
pharmacists willing to participate in research varies from 32 to 48% but only 6% of the 
surveyed pharmacists had ever participated in research (35-38). The study from Australia 
reported that pharmacists previously involved in research would much more readily 
consider future research participation (77%) than pharmacists who had never participated 
in research (34%) (38), (39). A Canadian study showed that pharmacists participate in 
research motivated by a general interest in clinical research, believing that participation 
will lead to better disease management and perceived patient benefits (19). The 
Australian survey quoted above mentions that approximately one-third of the responding 
pharmacists are nowadays, or had been in the past, involved in research activities, and 
generally reported positive experiences (34). 
Lack of time or experience and training in research appear as the main barriers to 
pharmacists’ participation in research (19, 35-37, 39, 34, 33, 40). This applies not only to 
pharmacists as well as doctors and nurses (41, 40, 42). Other barriers identified were: 
lack of monetary reward and/or fear that participation would lead to losing money; staffing 
challenges and fear that participation would draw the staff away from their primary 
assignments; communication problems between researchers and pharmacists; the 
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pharmacy mindset which has been described as a feeling of skills absence or knowledge 
and/or the need of a belief that participating in study would yield useful results; (38). 
The factors that encourage pharmacists to participate in research are (34): 
 desire to improve the career; 
 opportunity to learn more about disease management;   
 opportunity to provide enhanced services to patients;  
 personal interest. 
To overcome barriers to pharmacists’ participation in research strategies are proposed, 
such as having students conducting research in pharmacies, pharmacy research 
awareness programmes and encouraging and providing training to pharmacy staff 
members (38). Placing students in pharmacies to participate in research studies seems a 
good way to change their mindset in favour of research participation (33). However, 
neither this or the preceding strategies have been adequately tested, nor have any of the 
prior studies explained why some pharmacists participate in research despite all the 
identified barriers, while others find the barriers impassable (33). 
Understanding perceptions of time or lack of it appears to be a key to understand why 
healthcare professionals in general, and pharmacists in particular, find research 
participation challenging. In fact, the concept of time is shaped by the social context and 
the point of view of the person measuring it. It cannot be limited to an objective 
assessment of the number of hours required to complete research-related tasks (33). 
The Pharmacy SONAR project was a pilot study conducted from March 2008 to August 
2009 in ten community pharmacies in the greater Toronto area, Ontario, Canada, aiming 
to assess the feasibility of using an active surveillance system in which community 
pharmacies asked patients, who was picking up prescriptions, about their use of natural 
health products (NHPs) and possible related adverse events (AEs) (43, 33). A subsequent 
study explores how involved pharmacists perceived the barriers and facilitators related to 
participation in clinical research, in an attempt to understand pharmacy staff members’ 
experiences of participating in a pharmacy-based research study (33). 
The most important challenges related to participation in the SONAR study identified by 
the participants were (a) lack of time; (b) difficulty to remember asking the study 
questions; (c) perceived lack of knowledge about NHPs, and (d) communication difficulties 
(33):  
(a) Time - Time was identified as the biggest challenge to both participation in the 
study and good performance in the study. Although acknowledging that the three 
questions asked took a very short amount of time, the participants reported that 
the competing demands, on their time, made a few minutes seem difficult.   
(b) Remembering to ask the questions - It has been found that failing to remember 
to ask the questions and making this part of a daily work routine was, perhaps, 
even bigger obstacle for study participants. 
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(c) Perceived lack of NHP-related knowledge - Another issue found was that many 
pharmacists were hesitant to ask the probing questions because they were worried 
that the questions may encourage patients to ask additional information on NHPs. 
Pharmacy staff members felt inhibited due to their perceived lack of NHP 
knowledge, despite the NHP references provided and SONAR team support and 
follow-up.  
(d) Communication difficulties - Communication difficulties were identified between 
the study team and the pharmacy staff members and between the various 
pharmacy staff members themselves. The SONAR research assistant considered 
challenging to work with pharmacy owners or managers who were willing to allow 
their pharmacy to participate in the study, but whose pharmacy staff did not know 
what to expect and had trouble with the data collection itself.  
As seen above, this study was able to include pharmacy staff members in a research 
project and then analyse their perceptions for participation (33). However, given the case-
study design and convenience sampling, it is not clear whether the participating pharmacy 
staff members can be seen as representative of all pharmacy staff members in Canada or 
elsewhere. It is remarkable that approximately 75% of all pharmacies contacted by the 
study team turned down the offer to participate, giving just common reasons, where lack 
of time was the most significant one (33). It seems that some of the participating 
pharmacists were not comfortable in sharing their true opinion on this study and some 
have given polite but not truthful answers (33). It could also be noticed that there is some 
absence of clarity around the protocol, because participants did not give any real 
importance to data collection, reflecting their perception of the lack of value on research in 
general. The results of this study suggest that the “forgetting” was related to lack of clarity 
(33). 
On the other hand, although there was overwhelming recognition of clinical research’s 
value to the profession, few pharmacists possessed a good understanding of key terms 
related to research and evidence-based practice (e.g., P-value or number needed to treat) 
(34). 
It should be noted that this mindset about practice-based research should be changed 
since students enter pharmacy course in university. Kritikos et al., intended to show the 
undergraduate pharmacy students’ perception to research and their attitudes towards 
pharmacy practice research (PPR) through a 23-item survey (3). It was administered to all 
students enrolled in the 4th grade of pharmacy undergraduate programme of the 
University of Sydney (Australia). In total, 853 students responded to the survey leading to 
83% response rate. This study showed that while students perceived research to be 
necessary, they found it difficult and were divided in their interests in follow research. Most 
students agreed that pharmacy practice research plays an important part in the profession 
and curriculum but almost half of them lacked confidence to undertake it. The majority 
didn’t show positive attitudes towards the role of PPR in the curriculum, nor engaged in its 
activities, showed reliability on it, or expressed interest in college’s involvement and the 
role of PPR in the career (3). 
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This study might be of great importance whether it is intended to change pharmaceutical 
mindset to practice-based research. It is not just the pharmacists’ perception that matter, 
but also future pharmacists, those who are now at university. 
There are two key factors that might explain the relative lack of pharmacy practice-based 
research: lack of pharmacists’ knowledge and experience of research, and lack of 
understanding of the impact of pharmacists in health system (19, 44). 
 
 
3.4. COMMUNITY PHARMACY RESEARCH NETWORK (CPRN) 
 
As it was said before, the concept of using community pharmacies for practice-based 
research is relatively new. Moreover, little is known about community pharmacists’ 
willingness to participate in community-based research and the perceived barriers to 
participation (30). 
To assess the interest of American Pharmacy Services Corporation (APSC) independent 
community pharmacists to participate in a community pharmacy research network (CPRN) 
a study was conducted. It showed that in Kentucky the majority of pharmacists (83%) 
responding to the survey indicated that were “interested” or “very interested” to participate 
in a community pharmacy research network. Although respondents reported being willing 
to participate for about 6 hours per week in a CPRN, they pointed time as being the 
greatest barrier to participation (30). 
It should be noted that of 191 surveys sent to pharmacies, only 65 were returned (34%). 
The demographic information collected (including age, gender, pharmacy degree, and 
years of community practice) showed that the majority of respondents were males 
(58.5%) who were independent community pharmacy owners. The pharmacy’s data 
collected (including number of prescriptions dispensed per week, hours of operation, and 
staff number) also showed that more respondents worked in a rural pharmacy setting 
(72.3%) than in an urban one (27.7%) (30). 
This survey also included questions probing interest in CRPN participation (cf. Figure 7) 
and questions about perceived barriers. More than 42% of the respondents strongly 
agreed and 34.4% agreed that “community pharmacist play an important role in 
healthcare-related research”, while 21.9% disagreed and only 1.6% strongly disagreed 
with this statement. Pharmacists agreed that having the opportunity to affect the practice 
of community pharmacy and improve independent pharmacy services was the most 
important factor in deciding whether to participate in a CPRN. The opportunity to 
participate in a study that may be published in a journal and the opportunity to present the 
results of a research project at a regional or national level seemed to be less important for 
the study pharmacists. Job satisfaction would slightly increase for 51.6% of the 
respondents and financial compensation was ranked as the most important factor for 
participation by 16.4% of the respondents. Moreover 92.1% of the respondents indicated 
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they were interested in obtaining additional information about opportunities to participate 
in a CPRN (30). 
 
Figure 7. Level of interest in participation in a CPRN of independent community pharmacists (n=65) (adapted from (30)). 
 
This study also focused on the motivators that might influence pharmacists’ decision to 
participate in a CPRN. Figure 8 shows the importance of four motivators provided in this 
study: research assistant provided by the network; relief pharmacist provided by the 
network; becoming an advanced pharmacy practice experience (APPE) preceptor; and 
having the opportunity to suggest a research topic (30). 
 
 
Figure 8. Motivators in decision to participate in a CPRN of independent community pharmacists (n=65) (adapted from (30)) 
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The importance that each pharmacist gives to their participation in a CPRN also varies 
according to the importance they give to several factors. Figure 9 shows how the 
importance of various benefits of participating in a CPRN influence pharmacists’ decision 
to participate among four possible options. (30) 
 
 
Figure 9. Level of importance in decision to participate in a CPRN of independent community pharmacists (n=65) (adapted 
from (30)). 
 
CPRNs have the potential to be a valuable tool that pharmacies can use to solve issues 
related to the practice of pharmacy and improve patient care. However, as this study 
population consisted of independent community pharmacists who were members of an 
independent pharmacy cooperative, the results cannot be extrapolated to other practice 
settings and may not apply to independent pharmacists who are not members of a 
cooperative, whereby additional research is needed to capture the interest of pharmacists 
practicing in other settings (30). 
 
 
3.5. THE ROLE OF COMMUNITY PHARMACISTS IN CLINICAL TRIALS 
 
The primary objective of researchers of health services (including community pharmacies) 
in the conduction of randomised controlled trials (RCT) is to evaluate interventions to 
improve the organization, delivery, quality, and/or outcomes of care. The application of 
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these trials in academic or other settings allow a reasonable degree of control over key 
factors essential to conduct a well designed RCT. This enhances the internal validity of a 
study but may turn it less generalizable to non-academic settings (44). Weinberger et al. 
faced this issue on their study about the particular case of community pharmacies. They 
tried to describe unexpected challenges and possible strategies, when conducting 
randomised controlled trials of health services research interventions, in community 
pharmacies (44). 
With this purpose, they conducted an RCT to evaluate the effectiveness of an intervention 
to increase pharmacists’ involvement in caring for customers. They concluded that health 
services researchers should conduct RCTs in a variety of non-academic practice settings 
to increase generalizability and better reflect the true impact of interventions. Pragmatic 
problems, although significant, can be successfully overcome. The authors offer other 
investigators some advice, based on their experience: to conduct researches that are 
consistent with corporate goals; to involve the appropriate corporate persons early in the 
process and to be flexible. Summing up, the authors referred that conducting RCTs in a 
variety of practice settings should continue to be a goal for health services researchers 
(44). 
As it was said before, pharmacists are already becoming more “hands on” by measuring 
blood pressure or serum concentration. To participate in clinical research, pharmacists 
need adequate facilities, a good relationship with the public and general physicians, and 
strong professional motivation. Training would allow them to develop new skills (13). 
 
3.5.1.  RECRUITMENT 
 
The conduction of clinical trials has a determinant step concerning recruitment. Timely 
patient recruitment is widely acknowledged to be the single most important aspect for the 
success of a clinical trial ever since the recruitment process is often extensive, difficult and 
expensive. The restricted inclusion and exclusion criteria, the increased number of patient 
visits and a growing demand for participation from diverse populations, made trial 
protocols becoming much more complex hindering the recruitment process. All this 
implications lead to delays, which will extend the time to market for new drugs and could 
have additional costs to the sponsor (45, 46).  
There is a need to patients to be more aware of clinical trials and its participation benefits 
and opportunities. The source of information needs to be trustable so the patient can be 
confident that the participation is a good decision (45). The proximity patient-pharmacist 
that has showed so many benefits in so many distinct areas has also a useful impact. The 
decision to participate in a clinical trial is greatly affected by social, psychological and 
emotional factors (45). 
The participation of pharmacies in the recruitment process is not new. In fact, since the 
mid-1990s pharmacies have been used for patient recruitment. Nevertheless, the early 
programs only involved the notification of a pharmacy’s patients by letter that they might 
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be eligible for a nearby clinical trial (45). Nowadays the more common way to a patient be 
aware of a clinical trial is through the clinical trial sites and investigators, but their capacity 
to meet increasing demand for more patients and more diverse patient populations seems 
insufficient (45). 
The community pharmacy has gained an increasing important role on patients’ daily life, 
since patients visit their local pharmacies for basic healthcare needs. Moreover, the 
general public and pharmacists want the profession to be more proactive in disseminating 
information about clinical trials (45).  
Corelli et al. held a study that enhances the above said importance of pharmacies in the 
recruitment process. Study sites were 64 community pharmacies in Connecticut (n=32) 
and Washington (n=32) which due to their geographically disparate locations, gave rural, 
suburban and urban settings to the study (47). 
This recruitment process began with the identification of pharmacies. To identify potential 
participating pharmacies it was obtained a complete and current listing of licensed 
pharmacies. 
The process to determine interest in participation and confirm inclusion/exclusion criteria 
occurred over a period of time whereby the pharmacy contact was presented with the 
information and given time to consider participation and discuss with their staff 
(pharmacists and pharmacy technicians). Figure 10 (adapted from Corelli et al.) shows the 
recruitment and enrolment of participating pharmacies (47). 
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The study of Corelli et al. reveal that recruitment and consent of pharmacy personnel was 
a labour-intensive and time-consuming process requiring a median of 5 contacts over a 
median of 25 days (47). Efforts need to be implemented in community pharmacy 
participation in translational research. This would demonstrate the value of pharmacy 
services in health care system. It is important to engage pharmacy personnel to 
participate in “real-world” community settings in order to change small number of 
published studies within pharmacy-based research (47).  
 
 
Independent pharmacies enrolled 
(n=32) 
(16 in CT; 16 in WA) 
Community pharmacies (n=1678) 
(593 in CT; 1085 in WA) 
Chain pharmacies requiring 
corporate approval to participate 
(n=1233) 
Potentially eligible chain pharmacies 
(n=876) 
Chain pharmacies contacted (n=66) 
Did not meet inclusion criteria (n=1) 
Out of business (n=2) 
Unable to reach decision-maker (n=4) 
Time constraints (n=24) 
Other/unknown (n=3) 
Chain pharmacies enrolled (n=32) 
(16 in CT; 16 in WA) 
Mailed 
materials 
(n=16) 
Academic 
detailing 
(n=16) 
Randomization 
Potentially eligible independent 
pharmacies (n=445) 
Independent pharmacies contacted 
(n=84) 
Did not meet inclusion criteria (n=15) 
Out of business (n=4) 
Unable to reach decision-maker (n=5) 
Time constraints (n=16) 
Other/unknown (n=12) 
Mailed 
materials 
(n=16) 
Academic 
detailing 
(n=16) 
Randomization 
Figure 10. Recruitment and enrollment of participating pharmacies (adapted from (47)). 
Corporate (n=4) or regional (n=1)  
denials representing 357 
pharmacies 
(145 in CT; 212 in WA) 
CT: Connecticut WA: Washington 
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3.5.2. EDUCATION ABOUT CLINICAL TRIALS 
 
A 19 item public survey gathered on April 2010 (2650 people in 50 states and wide range 
of ages, health conditions, education levels, clinical trial knowledge, and pharmacy type 
used) tried to answer if pharmacists are a viable channel for education about clinical trial 
participation. It has been showed that 80% of respondents want their pharmacist to tell 
them about clinical trials. Nevertheless, 98% never asked a pharmacist for information 
about trials since the information given by their pharmacist is only 1% related to clinical 
trials (48, 49).  
In general, pharmacists give patients information about (48, 49): 
 the medicine (a printout on use/side effects) – 85% 
 the medicine (talks about use/side effects) – 40% 
 medicine that can be bought without a prescription – 24% 
 insurance – 21% 
 other treatments – 6% 
 doctors or hospitals – 3% 
 other information – 3% 
 clinical trials – 1% 
Surveyed people also refer they would like to receive information about trials from a 
pharmacist by printed information at the pharmacy (69%); email (49%); talking to a 
pharmacist at the pharmacy (40%); mail (21%); telephone (7%) or other (3%) (48, 49). 
56% of the surveyed patients would want to ask a pharmacist about how they can find a 
trial for themselves, a friend or family and 45% would ask if clinical trials are safe. 
Moreover, 44% would ask how they would learn more about trials, 32% wonder how do 
clinical trials work and 18% would question what is a clinical trial and 12% why are clinical 
trials needed (48, 49). 
On the other hand, a online pharmacists’ survey in 50 states gathered 213 respondents: 
69 community independent pharmacists, 62 hospital/institutional pharmacists and 82 
pharmacists in other settings. A mix of managers and front-line pharmacists who interact 
with patients revealed that they think it is very important to educate pharmacy 
patients/customers about clinical trial participation before they enrol (87%) (48, 49). 
The inquired pharmacists demonstrated they were somewhat willing (34%) or very willing 
(56%) to provide trial information if they knew that patients/customers were interested in 
receiving trial information. Pharmacists think the most effective means of providing 
information are conversation with patients/customers (75%), by a general education 
brochure (75%), by an automatically-generated list of appropriate trials (64%), an 
information kiosk (63%), conducting seminars (59%), an opt-in service to automatically 
receive information (54%) or showing a video (32%) (48, 49). 
Figure 11 shows the topics which pharmacists feel prepared to discuss with a 
patient/customer (48, 49). 
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Figure 11. Topics which pharmacists feel prepared to discuss with a patient/customer (adapted from (48, 49)). 
 
As it was said before, the lack of public awareness and understanding about clinical 
research has long hindered the efficiency and speed in recruiting patients to participate in 
clinical trials. It was found that only 1 in 3 adults had even heard of clinical trials (50, 45, 
51). The Center for Information and Study on Clinical Research Participation (CISCRP) 
showed that pharmacists might be a viable channel to educate and engage the public 
about clinical research, and the results suggested that pharmacy-directed outreach and 
education are feasible . 
Another study was conducted to verify the impact of in-pharmacy education on patient 
comprehension and willingness to participate in clinical research. In collaboration with 
McKesson and its network of independent community pharmacies, CISCRP trained 32 
pharmacists and provided them with educational materials to display and/or distribute at 
their pharmacies for a period of 2 to 3 months. Pre-surveys and post-surveys among 487 
patients were conducted to gather baseline measures and to assess the impact of 
educational materials and in-pharmacy discussions. A post-survey was also conducted 
among pharmacists. The results of the study showed that patient discussions with their 
pharmacists and revision of educational materials distributed through pharmacies 
positively impacted patient awareness, comprehension, and willingness to participate in 
clinical trials. Indeed, during the study period, 4% of patients who reviewed the materials 
chose to volunteer for clinical trials. Nearly all baseline measures of awareness and 
comprehension increased 10 to 20%. Respondents were more interested in learning about 
clinical research after speaking with their pharmacists and reviewing educational 
materials, and 40% were more likely to recommend participation to a friend or family 
member (48, 49). 
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4. CLINICAL RESEARCH IN A COMMUNITY PHARMACY SETTING 
– REAL-LIFE EXAMPLES  
 
 
The conduction of Clinical Research in the context of Community Pharmacies is already a 
reality. Several approaches may be use to bring Community Pharmacies into Clinical 
Research. 
 
4.1. RANDOMISED CLINICAL TRIALS ON STUDY DRUGS 
 
4.1.1. COMMUNITY PHARMACISTS AS LOCAL INVESTIGATORS IN A CLINICAL TRIAL: THE 
SINUTAB® STUDY 
 
A new formula of Sinutab® (Paracetamol 500 mg and Pseudoephedrine 30 mg) was 
approved for registration in Belgium. The registration was conditional since the regulatory 
authorities requested a clinical trial in order to prove the efficacy of the fixed combination. 
To meet this objective, a clinical trial was conducted in Belgian community pharmacies 
(52). 
The main objectives of the study of Laekeman et al. were the presentation of the clinical 
results of the trial and a reflection on the experience of conducting trials in a community 
pharmacy setting (52). 
It was a randomised, double blind, placebo-controlled, comparative phase 4 multicentre 
study in parallel between Sinutab® and placebo. Individuals were included if they were 
older than 18 years but excluded if they were using any medication possibly interfering 
with the study drug. In order to fulfil this requirement the medication history of all patients 
was available in the pharmacy’s computer (52). 
Aiming a target of 300 evaluable subjects, 451 subjects were included (mean age 38 
years). The treatment was established as follow: two Sinutab® or placebo tablets three 
times a day during 5 days (52).   
The setting of this study was Belgian community pharmacies with one community 
pharmacist per pharmacy as local investigator (n=35). The study was approved by 
University Hospital of Antwerp’s Ethics Committee and was externally audited (52). 
The main outcome measures of this study were (52): 
 Primary: “The effectiveness of Sinutab® on the relief of nasal congestion and 
headache in subjects with a common cold”  
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 Secondary: “The effectiveness on the Major Symptom Complex (MSC) of common 
cold; the number of days lost at work or school; the quality of life during daytime 
and at night; the time-to-resolution of the common cold; the overall safety of 
Sinutab®.” 
There were some parameters that changed significantly favouring Sinutab® over the 
treatment period: nasal congestion and headache (P < 0.001) (primary outcome); major 
symptoms complex (MSC) (P < 0.001); sore throat (P < 0.024); pressure around the eyes 
(P < 0.001); interference with concentration (P < 0.001); interference with sleep (P < 
0.066) (52). 
This study also paid attention to the adverse events (AEs). Those occurring more often 
were fatigue (37), dizziness (27), nausea (27), myalgia (18), sleep disorder (14), dry 
mouth (14) and upper abdominal pain (13). Apart from the myalgia, more subjects in the 
Sinutab® group suffered from these AEs than in the Placebo group (52). 
This study concluded that the combination of paracetamol with pseudoephedrine in 
Sinutab® improved significantly all symptoms towards placebo and that no serious 
adverse events occurred (52).  
Since this was the first clinical trial of this dimension with community pharmacists taking 
clinical responsibility as local investigators, the authors stated that they acquired skills and 
knowledge which could be used in the future and the knowledge would be spread (52). 
 
 
4.2. RANDOMISED CLINICAL TRIALS ON PHARMACEUTICAL INTERVENTION 
PROGRAMS 
 
4.2.1. EFFECTIVENESS OF A COMMUNITY PHARMACIST INTERVENTION IN D IABETES 
CARE: A RANDOMISED CONTROLLED TRIAL 
 
To date, European studies on the impact of community pharmacist interventions in 
Diabetes are scarce. There is little evidence from well designed randomised controlled 
trials about the impact of community pharmacist’s intervention on the clinical management 
of patients with type 2 Diabetes (53). 
To address this evidence gap, an RCT was initiated in Belgium, in order to study the 
effectiveness, and sustainability of effects, of a community pharmacist intervention in 
Diabetes care (53). 
Mehuys et al. carried out a 6-month, randomised, controlled, parallel-group trial in 66 
community pharmacies in Belgium. The pharmacists’ participation in this study was 
voluntary and the recruitment was made through a call by three professional pharmacist 
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associations. Each pharmacy was asked to recruit five patients and each participant’s 
physician was informed about the study by letter (53). 
This study follows the same rules than other clinical trials in what concerns performance 
according to Declaration of Helsinki and GCP guidelines. It was approved by Ghent 
University Hospital’s Ethics Committee and it was given written informed consent (53). 
In this study, randomisation was made at the pharmacy level: each participating pharmacy 
was randomly assigned to either the control group or the intervention group. Patients in 
the control group received usual pharmacy care, while patients in the intervention group 
received a protocol-defined intervention at the start of the study and at each prescription-
refill visit, during the study (53). 
The intervention design was based on previous observational data concerning Diabetes 
management in Belgium (54): 
 Education about type 2 Diabetes and its complications; 
 Education about the correct use of oral hypoglycaemic agents (timing in relation to 
food); 
 Facilitation of treatment compliance (by counselling); 
 Healthy lifestyle education (diet, physical exercise and smoking cessation); 
 Reminders about annual eye and feet examinations. 
The elements above were implemented by the pharmacist on each visit of the patient 
during the 6-month intervention period (53). 
It should be noticed that before the start of the study, the intervention pharmacists 
underwent a training session to understand the study protocol and to deepen knowledge 
on the pathophysiology of type 2 Diabetes and its non-pharmacological and 
pharmacological management according to current treatment guidelines. The control 
pharmacists only received training on the study protocol (53). 
This study mainly focused on correct medication use, medication adherence and healthy 
lifestyle promotion. It showed that the community pharmacist intervention significantly 
reduced HbA1c (between-group difference: 0.5%, P=0.009) (53). 
 
4.2.2. RANDOMISED CONTROLLED TRIAL PROTOCOL ON INTERVENTION IN 
DEPRESSED PRIMARY CARE 
 
Pharmaceutical Care Program for Pharmacological Treatment of Depression in Primary 
Care (PRODEFAR) consists of a series of educational interventions focused on improving 
patients’ knowledge of antidepressant medication, as well as making patients aware of the 
importance of compliance to the medication. The PRODEFAR study intends to evaluate 
the effectiveness and cost-effectiveness of a community pharmacist intervention 
developed to improve patients’ compliance and outcomes of primary care patients with 
depression, providing valuable information for health professionals and policy makers. 
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This trial, held in Barcelona (Spain), compares patients receiving a pharmaceutical care 
support program in primary care with patients receiving usual care (55). 
The importance of including community pharmacists, who are considered the health 
professional most readily accessible to patients, as active members of multidisciplinary 
healthcare teams was emphasized by the World Health Organisation (WHO) and the 
European Council. Community pharmacies have shown improvement in patient wellbeing, 
in chronic physical conditions (55).  
Therefore, this study aims to evaluate the efficacy of a pharmaceutical care program, 
compared with usual care, on the improvement of adherence to anti-depressant drugs and 
patient wellbeing in a population with a diagnosis of depression treated in primary care 
under real practice circumstances (55). 
The methodology used on this study was a 6-month follow-up naturalistic randomised 
controlled trial with random allocation of participants into two alternative branches: usual 
medical and pharmaceutical care plus support programme in community pharmacy 
(intervention group) and usual medical and pharmaceutical care (control group), as 
described in Figure 12 (55). 
 
 
Two of the inquired pharmacies (13%) refused to participate in the study due to deep 
workload and lack of interest in the study. Therefore, 13 pharmacies with a total of 34 
pharmacists would be responsible for providing patients with the intervention and usual 
care during the 6 month follow-up period (55). 
Since it was a randomised clinical trial, randomisation was generated at the patient level 
by a computerized random-number generator with a ratio 1:1. Then, when the patient 
Figure 12. Study Design (adapted from (55)). 
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went to the pharmacy and gave the prescription to their pharmacist, they opened the 
envelope and created a patient study chart distinguishing between control and 
intervention group. The blinding of participants or pharmacists (investigators) is not 
possible due to the type of intervention (55). 
In this study, patients enrolled to the intervention group would receive the support 
program in community pharmacy (PRODEFAR) every time they went to pharmacy to pick 
up the prescription or asked advice in the 6-month duration of the study (55). 
The participation in this study required the pharmacists to be trained. In this case, 
pharmacists participating in the study received 8 hours of training about PRODEFAR prior 
to the study. Obviously, patients in the intervention group were asked to avoid 
conversations regarding the program with patients of the control group, in order to prevent 
bias. The measurements of this study were made through assessment visits (at baseline, 
3 and 6 months) conducted by independent and blinded interviewers (55). 
 
 
4.3. REAL WORLD DATA ON PRE-LICENSES 
 
The Salford Lung Study is the world’s first pragmatic Randomised Clinical trial (pRCT) to 
compare the real-world effectiveness in routine primary care of a novel once-daily 
investigational treatment with existing therapy for chronic obstructive pulmonary disease 
(COPD) and asthma (58, 59). Pre-license pRCT are large prospective clinical studies in 
which patients are randomised to two or more interventions, and then followed up 
according to the investigator physicians’ usual practice. They differ from other RCTs just 
because they measure effectiveness (benefit the treatment produces) in routine clinical 
practice (59, 56, 57). 
The Salford Lung Study is an open-label phase III pRCT in which Patients are randomised 
to receive either a continuation of their usual treatment or a novel once-daily Dry-Powder 
Inhaler (DPI) containing a combination of a new inhaled steroid and a new long-acting β-
agonist (LABA) - fluticasone furoate/vilanterol (FF/VI) – Ellipta® (59, 56, 57). 
After randomisation, patients receive ‘usual’ care for 12 months by their own general 
practitioner (GP), practice nurse and community pharmacist. In this way, community 
pharmacies are taking part in a phase III clinical trial.  All community pharmacies in the 
Salford area of Greater Manchester have been given the chance to contribute to this 
clinical effectiveness trial developed by GlaxoSmithKline (GSK) (57). 
GSK has paid for over 500 pharmacists, dispensing staff and counter assistants to be 
trained according to Good Clinical Practice requirements for the conduction of clinical 
trials. This training encompasses to handle the investigational treatment and complete the 
necessary labelling and record keeping. Pharmacy staff has been explained to treat 
patients in the trial arm as they would a normal patient, meaning no extra patient reviews 
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or counselling are required as part of the study. On the other hand, the staff is expected to 
take care and report any adverse reactions. Moreover, although patients who are 
allocated to the study therapy will be trained how to use the new inhaler by a practice 
nurse, community pharmacies in the area are also equipped with a placebo inhaler so 
pharmacists can demonstrate inhaler technique to the trial participants, if necessary (57). 
The primary outcome for COPD is the rate of moderate and/or severe exacerbations. In 
the asthma study, the primary outcome is an improvement in asthma control (Asthma 
Control Test). A full regulatory package for FF/VI is under consideration by the European 
Medicines Agency, and at the time of the study’s initiation, extensive efficacy and safety 
data were already available for more than 6400 patients from completed RCTs (59, 60). 
Effectiveness and safety data are monitored and collected in near-real time using an 
electronic health record, minimising the number of patient visits required. GPs prescribe 
as usual, patients order and collect repeat prescriptions in their usual way and their study 
medication from their usual community pharmacist (59, 60). 
This study faced some design challenges. The key objectives in designing and executing 
the Salford Lung Study were: enable collection of data with minimal disruption to normal 
care, enrol a large proportion of the local patient population, provide appropriate safety 
monitoring and meet all ethical and regulatory requirements. In the study’s planning 
stages, the study sponsor and partners took advice from independent experts, including 
the Medicines and Healthcare Regulatory Authority (MHRA), the National Institute for 
Health and Care Excellence (NICE) and the National Institute for Health Research (NIHR), 
as well as the National Research Ethics Service Committee NorthWest, Greater 
Manchester South (59, 60). 
The need of rigorous safety monitoring of phase III trials is provided in the context of usual 
care by remote monitoring using the Salford Integrated Record (SIR). Formal study visits 
are only required at baseline (consent and randomisation) and at the end of the study. 
Telephone calls every 3 months act as a ‘safety net’ if there has been no other contact 
between a patient and their GP (59, 60). 
The first patients were enrolled for COPD study in April 2012 and for asthma study in 
December 2012. By mid-October 2013, more than 2000 patients gave consent and 1600 
patients were randomised in the COPD study, on schedule for a target of 2800 by end of 
March 2014, with first results expected on second quarter of 2015. The asthma study 
recruitment is now accelerating, and likely to be complete 6 to 12 months later (59, 60). 
The study execution has required intensive collaboration across the National Health 
Service, with the NIHR, MHRA, Ethics Committee, Academia and Industry. The creation 
of an effectiveness study environment in Salford serves as a benchmark for other 
initiatives, including pharmacovigilance and phase IV studies, to collect data from primary 
and secondary care anywhere in the UK. (59, 60) Such initiatives redesign the future of 
clinical trials and meet the demand for value-based medical evidence.  
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5. CLINICAL RESEARCH – THE PORTUGUESE REALITY  
 
 
The possibility of conducting clinical research in Portugal involves interaction of various 
stakeholders. The majority of clinical trials in Portugal are promoted by multinational 
pharmaceutical companies of Research & Development (R&D). 
However, the number of submitted clinical trials in Portugal between 2006 and 2012 fell by 
26%, from 160 to 118 studies (10). The decrease in the number of clinical trials being 
performed in Portugal is revealing data from a progressive loss of competitiveness. 
In this context, it is necessary to recognize that there is an opportunity to improve and 
promote the necessary communication between all stakeholders. 
Community pharmacies constitute themselves as a possible partner in this scenario. 
 
5.1. PORTUGUESE AUTHORITIES 
 
5.1.1. INFARMED 
 
When starting this work, the conduction of clinical trials on medicinal products for human 
use was regulated by Law No. 46/2004, of 19th August. (61) According to this law, and 
Infarmed procedures, the submission of a Clinical Trial Application (CTA) to Infarmed 
should be done in a mixed format (paper and CD-ROM) (62). 
The information to be sent to Infarmed considering a CTAs and any changes thereafter 
shall be provided in electronic format as set out in the respective Instructions to Applicant. 
This format allows the automatic integration of this information in support of the 
assessment system in the Institute, optimizing the management, access, and archiving of 
processes throughout product’s lifecycle. These instructions are the framework for 
organizing the elements in electronic format (CD-ROM) to submit to Infarmed and the 
procedure for the respective use. The indicated structure should not be changed and 
names assigned to each folder should be respected. (62) 
Infarmed conducts inspections to clinical trials conducted in Portugal, as well as in other 
countries (European Union and third countries). These actions seek to verify compliance 
with Good Clinical Practice in the conduct of clinical trials, verification of compliance with 
Good Manufacturing Practice (GMP) for medicinal products, verification of Good 
Laboratory Practice (GLP), where applicable to clinical trials, as well as other rules and 
legal provisions in accordance with national and European Community legislation. 
Inspection activities involve sponsors, researchers, manufacturers, analytical laboratories 
and others, as well as any site directly or indirectly related to clinical trials conduction (63). 
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5.1.2. CEIC 
 
Clinical research follow ethical references to promote the respect of all human beings, 
protect their rights and health, especially those submitted to clinical research. Ethics 
Committees have an essential role in the protection of subjects (64). 
CEIC (Comissão de Ética para a Investigação Clínica – Ethics Committee for Clinical 
Research) was established by Law No. 46/2004 and it is guided not only by legal 
standards, but mainly by ethical principles aiming the respect of human rights (64). 
According to Law No. 46/2004, of 19th August, CEIC is an independent organism, 
constituted by individuals related to health and other activity areas, whose mission is to 
ensure rights, safety and well-being protection of the participants in clinical trials, through 
the issue of an ethical opinion on the submitted clinical trial protocols. In order to meet this 
objective, CEIC makes a preliminary assessment monitoring of all clinical trials of 
medicinal products for human use. In this context, CEIC evaluates (65): 
 relevance and design of the research protocol; 
 risk-benefit profile of the intervention; 
 ability of the research team; 
 human and material resources available in research centres; 
 compensation; 
 insurance; 
 amounts and terms of payment for researchers and participants;  
 methods of recruitment; 
 circuit and accessibility of experimental medicinal product; 
 guarantee of volunteers’ autonomy - particularly regarding the nature and 
adequacy of the information to be provided and the procedure for obtaining 
informed consent. 
 
 
10 7 
17 
8 8 9 5 
14 
23 
19 
13 
9 
72 
53 51 
58 
62 
47 
63 
48 
54 57 
45 42 
0 
10 
20 
30 
40 
50 
60 
70 
80 
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 
Clinical Trial Substantial Amendment 
Figure 13. Number of Submissions to CEIC in 2013 (N=794) (adapted from (66)). 
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Figure 13 shows the total submissions to CEIC in 2013. Total submissions were 
calculated considering the number of total submitted processes to CEIC during the 
corresponding reported period (year 2013), and excluding cancelled processes (66). 
Table 3 shows the number of days to issue a final opinion by CEIC. This number of days 
was calculated considering the period between the date of submission and the date of 
issuing the letter of plenary deliberation (excluding the time used by the sponsor for 
additional clarifications); total time for issuing an opinion included the time used for 
additional clarifications (66). This is an important delay issue concerning clinical trials 
initiation in Portugal. 
 
Table 3. Descriptive Statistics about the time (days) to issue the final opinion, per type of application, in 2013 (adapted from 
(66)). 
 Type of Application 
 Substantial Amendment Clinical Trial 
 Average Median Minimum Maximum N Average Median Minimum Maximum N 
1
st
 
Quarter 
27.8 27 5 65 124 44.3 38 18 73 31 
2
nd
 
Quarter 
30.3 28 7 96 150 45.1 41 19 97 28 
3
rd 
Quarter 
26.3 25 7 59 148 43.1 41 20 76 19 
4
th 
Quarter 
27.9 27 5 61 138 38.8 36 13 75 30 
TOTAL 28.1 27 5 96 560 42.0 39 13 97 108 
 
The graphics presented in Figure 14 show the proportion of favourable and unfavourable 
opinion issued by CEIC in 2013. Figure 15 show the number of opinions issued by 
therapeutic area (66)  
 
Figure 14. Favourable and Unfavourable opinions (% of total) (New Trials, N= 108; Substantial Amendments, N=559) 
(adapted from (66)). 
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Figure 15. Number of opinions (Clinical Trial) by Therapeutic Area (N=108) (adapted from (66)).   
 
With the entry into force of the new Law of Clinical Research (Law No. 21/2014, of 16th 
April) the role of CEIC is strengthened. It is expected that the statistics of time for 
opinion’s issue come down in the forthcoming years, with the reduction of the deadline 
imposed by Law (67). 
 
5.1.3. CNPD 
 
The National Commission for Data Protection (CNPD) is an independent administrative 
authority. Generally, it supervises and monitors the processing of personal data in strict 
respect for human rights and freedom and guarantees protected in the Constitution and 
the law. The Commission is the National Supervisory Authority for Personal Data. Rights 
relating to the use of information technology are enshrined in the Constitution and 
developed by the Data Protection Act (68). 
CNPD issued a Deliberation regarding research studies on health (Deliberação 
nº227/2007). CNPD stated that this kind of studies use various designations related to 
different objectives, methodologies and categories. This Deliberation relates to 
observational or epidemiologic studies, retrospectives and/or prospective (69). 
The processing of data in order to perform health research studies focus on sensitive data 
and are therefore subject to control, according to paragraph a) of 28th article of Data 
Protection Law. In this way, these studies could not be performed before CNPD’s prior 
authorisation. CNPD assess whether the treatment is according to data protection 
principles. Moreover, personal data used should be adequate, relevant and not excessive 
regarding its goal (69). 
The following kind of data should be proved deemed necessary for the continuation of the 
study (69): 
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 Identification data;  
 Health data (Clinical history/medication/exam results)  
 Familiar history (health information/genetic information)  
 Personal habits;  
 Data related to professional activity;  
 Data related to clinical study.  
On the other hand, CNPD has also issued a Deliberation specifically for clinical trials 
(Deliberação nº333/2007). This Deliberation imposes not only scientific and technical 
requirements but also legal, juridical and ethical requirements to clinical studies. Clinical 
Trials Law (Law No. 46/2004, of 19th August) obliges as a minimal condition that patients’ 
protection is guaranteed through right to privacy and protection of personal data of 
individuals, in accordance with their legal systems. (70) 
 
 
5.2. CIRCUIT OF THE EXPERIMENTAL DRUG 
 
In Portugal, “pharmaceutical act” is defined in the legislation (Decree-Law No. 288/2001, 
of 10th November) as (71):  
 Development and preparation of the pharmaceutical form of medicines; 
 Registration, manufacturing, control of medicines of human and veterinary use and 
of medical devices; 
 Quality control of drugs and medical devices in laboratory of quality control of 
medicines and medical devices; 
 Storage, conservation and wholesale distribution of medicines for human and 
veterinary use and of medical devices; 
 Preparation, control, selection, acquisition, storage and dispensation of medicines 
of human and veterinary use and of medical devices in community pharmacies, 
hospital pharmaceutical services and public and private pharmaceutical services of 
any other entities; 
 Preparation of antiseptic solutions, disinfectants and intravenous mixtures;  
 Interpretation and evaluation of medical prescriptions; 
 Information and consultation on medicines for human and veterinary use and on 
medical devices, in order to promote its correct use subjected, or not, to medical 
prescription, next to healthcare professionals and patients; 
 Accompaniment, vigilance and control of distribution, dispensation and use of 
medicines of human and animal use and of medical devices; 
 Drug monitoring, including determination of pharmacokinetic parameters and the 
establishment of individualized dosing regimens; 
 Collection of biological products, execution and interpretation of clinical analysis 
and determination of serum levels; 
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 Execution and interpretation of toxicological, hydrological and bromatological 
analysis. 
Pharmaceutical services are solely responsible for the investigational medicinal products 
and its circuit. The management process should be made to ensure safety, accountability, 
transparency and traceability. 
Pharmaceutical services are responsible for the following processes (64): 
(a) Reception – It should be ensured that study products (including placebo and 
concomitant medication) could only be delivered to pharmaceutical services where 
the clinical site is integrated, to the responsible pharmacist, or a deputy, 
designated by the director of service. 
(b) Storage and Dispensing – The access to the investigational medicinal product 
could only be done by the responsible pharmacist or other designated pharmacist. 
The same goes for dispensing (directly to the patient or to nurses). Enhanced 
stocks in clinical services involved in the trial may be accepted, for drugs 
administrated in an urgent/emergent setting, although under supervision of the 
pharmaceutical services. 
(c) Preparation of IMP – For drugs that require preparation procedures (cytotoxic, 
anti-infectives, nutrition, etc.) pharmaceutical services may use their own 
resources, meeting the applicable technical requirements. 
(d) Administration of IMP 
(e) Devolutions – The applicable procedures should be described and in accordance 
with the applicable legislation. It should be clear the mandatory collection of empty 
packaging and remaining medicines. 
(f) Investigator’s Brochure (IB) and Authorisation – Prior to trial initiation, up-to-
date protocol should be available in the pharmaceutical services, as well as a copy 
of the authorization to start. Access, when needed, to the IB should also be 
ensured by the research team and other health professionals involved in 
investigational medicinal product circuit. 
(g) Forms – Templates (forms) to be used for prescribing, dispensing and record the 
preparation and administration of the investigational medicinal product should be 
included. 
According to point 1 of article 41º of Law No. 46/2004, of 19th August in healthcare 
institutions incorporated into National Healthcare Service, experimental drugs and devices 
used for its administration, as well as other medicines already authorized which are 
necessary to the trial, must be stored and dispensed by the hospital pharmaceutical 
services (61). 
The circuit of the experimental drug is a technical and logistic responsibility of the 
pharmaceutical services of the sites where the clinical trials are being conducted. In 2013, 
CEIC has issued an opinion regarding the circuit of experimental drugs. 
It was CEIC opinion that the principles established in article 41º of Law No. 46/2004 
should be extended and generalized to all healthcare units, which are constituted as 
clinical trials sites (64). 
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According to point 4.6.2 of ICH GCP E6 Guideline where allowed/required, the 
investigator/institution may/should assign some or all of the investigator's/institutions 
duties for investigational product(s) accountability at the trial site(s) to an appropriate 
pharmacist or another appropriate individual who is under the supervision of the 
investigator/institution (4).  
With these assumptions, CEIC has outlined a set of guidelines for the implementation of 
the experimental drug circuit coordinated with the respective hospital pharmaceutical 
services (64): 
 Minimum operating conditions: Pharmaceutical services in hospitals and 
healthcare units in which clinical trials are conducted should present a segregated 
area for the experimental drug, responsible for the integrity of the experimental 
drug circuit. 
o Physical conditions: These areas must have the following minimum 
physical requirements:  
 Proper space with restricted access;  
 Structures for storing confidential documents;  
 Suitable structures for storage of experimental drugs (separated by 
clinical trial; refrigerators with redundancy own power and audible 
alarms; separate quarantine area; calibrated monitors for 
temperature and humidity;  
 Access to the white area for handling drugs, when necessary; 
o Human resources: All pharmacists involved in clinical trials should be 
trained in Good Clinical Practice and Good Pharmaceutical Practice. The 
pharmaceutical services shall formally indicate the responsible for 
investigational medicinal products which should be responsible for 
managing samples 
The documentation to be available to pharmaceutical services, before the start of the 
study should consist at least of (64):  
 Protocol approved by regulatory authorities;  
 Investigator’s Brochure and/or SmPC of the drugs involved in the study protocol 
approved by regulatory authorities;  
 Copies of certificates of batch release of drugs and/or investigational medicinal 
products. 
In case that these healthcare units are not provided with pharmaceutical services, as 
happens with Primary Healthcare Units, an alternative should be found. 
OF (Ordem dos Farmacêuticos – Pharmacists’ Association) has also issued an opinion on 
this issue. According to them, CEIC proposed that when healthcare units are not provided 
with pharmaceutical services, the monitoring of the experimental drug circuit should be 
ensured by the pharmacist of the clinical trial monitoring company. However, OF proposed 
that Regional Health Administration create research teams for the Health Center, involving 
Community Pharmacies from the involving area, once they have training in clinical trials 
and facilities and procedures approved by Infarmed. Thus, similarly to the hospital 
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pharmacies, community pharmacies would ensure the circuit of experimental medicine as 
members of the research team, working in combination with the medical staff towards the 
patient ambulatory (72). 
It is our understanding that community pharmacies when participating in a clinical trial in 
partnership with a primary healthcare unit might play the same role of pharmaceutical 
services in hospitals.  
Community pharmacies may be the place where the investigational product is stored and 
dispensed to the patient; or, on the other hand, might just be the place of storage of the 
investigational product, being dispensed at the primary healthcare units.  
The involvement of an external entity (with a different location) leads to the need of 
greater heed and accurate documentation of the entire circuit. Since the participation of 
community pharmacies in clinical research, particularly in clinical trials, led to a change in 
the circuit of experimental medicine as we know it (and described above). 
The privileged location of the Portuguese community pharmacies in the community and its 
technical resources make them capable of performing this role in an integrated manner 
with the primary healthcare units. 
However, also in this case as already happens in most clinical trials, feasibility should be 
assessed in a case-by-case basis. 
 
 
5.3. PORTUGUESE NEW LAW ON CLINICAL RESEARCH – LAW NO. 
21/2014, OF 16TH APRIL 
 
During the elaboration of this work, Portugal saw approved a new Clinical Research Law 
(Law No. 21/2014, of 16th April) that would come into force on 16th June (67). 
It regulates the clinical research considered as all systematic studies intended to discover 
or verify the distribution or the effect of health factors, conditions or health outcomes, 
processes of health and disease, performance, and, or safety interventions or provision of 
healthcare (67). This Law replaced the Law No. 46/2004, of 19th August known as Clinical 
Trials Law which approved the legal regimen applicable to the performance of clinical 
trials of medicinal products for human use (61). 
Clinical Research Law covers clinical trials with medicinal products for human use and 
clinical research of medical devices. Once the scope of the new legislation is much larger 
than the previous Law of Clinical Trials, many concepts are revised to encompass all 
these types of research. 
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This Law also determines a great reduction in timeframes for approval. For example, the 
time to issue of opinion by Ethics Committee reduces from 60 to 30 days for new clinical 
trials and from 35 to 20 days for protocol amendments. 
It also determines that the request for opinion shall be done through RNEC (Registo 
Nacional de Estudos Clínicos – National Register of Clinical Studies). RNEC is an 
electronic platform for the registration and disclosure of clinical studies, which promotes 
the interaction between all stakeholders in the clinical research field, facilitating and 
encouraging the development of high quality research for the benefit of patients as well as 
the dissemination of national clinical research to the general public, professionals and 
researchers. RNEC works next to Infarmed and it is coordinated by a commission 
constituted by a representative of Infarmed (presiding), a representative of CEIC and a 
representative of National Institute of Health Dr. Ricardo Jorge, designated by the 
member of the government responsible for the health sector (67). 
The objectives of RNEC are as follow (67): 
 Establish a public registry of clinical studies, researchers, clinical studies centres, 
sponsors, CEC (Comissão de Ética Competente – Competent Ethics Committee) 
opinions, publications, research instruments, while respecting the rights of the 
sponsor and the investigator in what concerns intellectual property; 
 Provide information to support clinical studies in Portugal, throughout their various 
stages, including the various electronic forms for submission to CEC, Infarmed, 
and other entities;  
 Identify relevant knowledge areas to each participant in clinical studies; 
 Create a website with relevant information on clinical studies, clinical studies 
centres, reports and studies on clinical research in Portugal;  
 Spread and promote training opportunities in clinical trials field;  
 Foster collaboration among sponsors, investigators and centres of clinical studies; 
 Promotion of public and private services in support of clinical studies as well as 
national resources to support research, including clinical registries, biobanks, and 
clinical and genetic databases, and centres of excellence;  
 Promotion monitoring indicators of the various stages of the process, in particular 
relating to the submission, approval and implementation of the clinical studies;  
 Provide ongoing evaluation of response capability of the authorities responsible for 
the approval and implementation of the clinical studies;  
 Contribute to the internationalization of clinical research, providing supportive 
elements for performance of studies in Portugal addressed to researchers and 
foreign sponsors; 
 Provide or, when not possible, state publications, presentations and reports arising 
from the realization of registered clinical studies; 
 Provide the design, instruments of data collection of public domain and databases 
metadata, avoiding duplication of studies and fostering collaboration between 
researchers; 
 Provide a public version of the database of clinical studies, mandatorily for clinical 
studies with direct or indirect financing from public funds, duly authorized by the 
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CNPD and respecting the rights of the sponsor and the investigator in what 
concerns intellectual property within three years after completion of the registered 
clinical study; 
 Continually assess and monitor the performance and quality of clinical research in 
Portugal; 
 Contribute to the promotion of literacy and the social dissemination of the role of 
clinical research; 
Infarmed should assure the articulation of RNEC with database information, health and 
safety vigilance systems, as well as public registries of clinical studies and scientific 
repositories, promoting information standardization, interoperability and communication 
between them (67). 
For the conduction of clinical studies, investigators and their teams, sponsors, monitors, 
CES and clinical studies centres shall be registered in RNEC. Likewise, the investigator or 
the sponsor should register the clinical trial or interventional medical device clinical study 
on RNEC prior, or at the same time, of the request for an opinion to CEC or the 
authorisation application to Infarmed. Publications, presentations and reports relating to 
clinical trials, shall be made available by the investigator or the sponsor within 30 days 
after their publication (67). 
Portuguese New Law on Clinical Research (Law No. 21/2014, of 16 of April) (67), 
introduced the concept of qualified pharmaceutical service which is a service that has an 
authorisation for direct acquisition of medicines issued by Infarmed. This authorisation 
identify the responsible pharmacist, who should have good clinical practice training and 
ensure compliance with the requirements of storage and circuit of experimental drugs and 
medical devices used for its administration, as well as other authorised medicines. The 
qualified pharmaceutical service should also have an authorisation for direct acquisition of 
narcotic and psychotropic substances (if the pharmaceutical service handles this kind of 
substances).  
According to this Law, pharmaceutical services are responsible for reception, storage, 
preparation, dispensation, collection and return or destruction of the medicinal product, 
having the duty to prepare a document describing the experimental drug containing circuit 
elements relating to the receipt, storage, dispensing and administration of the 
experimental drug.(67) 
 
 
5.4. STUDIES PERFORMED IN THE PORTUGUESE COMMUNITY 
PHARMACIES SETTING  
 
In Portugal, the conduction of clinical trials in cooperation with community pharmacies is 
not yet a reality as well known as it was demonstrated above for other countries. A search 
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on clinicaltrials.gov for "community pharmacy" found 47 results . The same search in the 
European register of clinical trials (https://www.clinicaltrialsregister.eu) reveals just 1 
result. The Portuguese portal of clinical trials, does not yet have this kind of information. 
However, it is expected that this would change with the implementation of the new Law of 
Clinical Research. 
On the other hand, it is possible to verify that the Portuguese community pharmacies 
already play an important role in conducting observational studies in Portugal, notably by 
CEFAR (Centro de Estudos e Avaliação em Saúde - Centre for Health Evaluation & 
Research) (76). 
An observational study was performed in seven Portuguese community pharmacies 
between October 2002 and July 2003. This study aimed to analyse and characterize 
demographic, clinical and therapeutic aspects, in a group of individuals with type II 
Diabetes. In this study, the methodology was based in a systematic selection of 150 
patients for which an assessment questionnaire was implemented (77). 
This transversal, observational and multicentre study measured blood glucose levels, 
blood pressure, body mass index, family history of Diabetes and drug intake. Each 
responsible pharmacist (after receiving specific training) administered the questionnaire  
presented in Figure 16 to the type II diabetics (77). 
 
 
Pharmacy:_______________________________________________________ 
Pharmacist:______________________________________________________ 
 
 
Variables Data 
Time to complete the questionnaire (hour/min) Start/End 
Date  
Name  
Telephone / Mobile phone  
Age (years)  
Sex (F/M)  
Weight (Kg)  
Height (m)  
Family history (Y/N/DK)  
Duration of diagnosis (years/months/weeks/days)  
Hypoglycemia(s) (if ever felt dizziness, tremors, visual changes, sweating, 
palpitations, dizziness or passed out) (Y/N) 
 
Opinion about Diabetes control (1.G; 2.R; 3.B)  
Self-monitoring (Y/N)   
Capillary glycaemia (cg), glycosuria (gu) or both (cg+gu) (Y/N)  
Fasting glucose (mg/dL) (at least 2hours fasting)  
Total Cholesterol (mg/dL)  
systolic blood pressure (mmHg)  
Diastolic Blood Pressure (mmHg)  
Antidiabetic (1)  
Antidiabetic Dose /day (1) (mg)  
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Antidiabetic (2)  
Antidiabetic Dose /day (2) (mg)  
Antidiabetic (3)  
Antidiabetic Dose /day (3) (mg)  
Insulin (Y/N)  
Antihypertensive (1)  
Antihypertensive (2)  
Antihypertensive (3)  
Antidyslipidemia (1) etc  
  
 
Figure 16. Questionnaire of registration of study variables (adapted from (77)).  
 
This data collection instrument included 3 types of variables: demographic (sex and age), 
clinical (capillary glycaemia, systolic and diastolic blood pressure, total cholesterol, 
occurrence of hypoglycaemia, self-monitoring, familiar history, diagnosis duration and 
opinion on disease control)  and therapeutics (oral antidiabetic drugs and daily doses, 
antihypertensive drugs and antidyslipidemic drugs). This study was able to conclude that 
clinical variables of participant patients were not reasonable. This might not be a 
representative sample of the Portuguese population, but may be taken as a good 
indicator, for the analysed year (2003) (77). 
Observational studies are a great tool to identify important health issues on the population 
and to find a way to overtake them. Portuguese community pharmacies may also have an 
important role on the development of this kind of studies, because they have access to a 
large population and proper knowledge about several diseases. Nowadays, the studies 
are considered to be of great importance since they can give us real world data.  
 
B: bad; cg: Capillary glycaemia; DK: don’t know; F: female; G: good; gu: glycosuria; M: male; N: no; R: reasonable; Y: yes 
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6. THE NEXT STEP - APPLICATION OF A QUESTIONNAIRE  
 
 
The lack of information concerning Clinical Research in Portuguese Community 
Pharmacies makes it necessary to assess the interest of Portuguese Community 
Pharmacies in participate in this kind of research. In this way, the survey established by 
Carr MB et al. (cf. Figure 17) might be of great interest (30). In their study, Carr MB et al. 
intended to assess the interest of American Pharmacy Services Corporation (APSC) 
independent community pharmacists in participating in a community pharmacy research 
network (CPRN) and to identify perceived barriers to participation in a CPRN.  
 
 (You may skip any question(s) that you do not want to respond to and you may stop answering questions at 
any time) 
Section I – Demographic Information 
1. How old are you? _______(years) 
2. What is your gender? _____________ 
3. How long have you been practicing pharmacy? _______(years) 
4. How long have you been in community practice? _______(years) 
5. How long do you plan to practice pharmacy? _______(years) 
6. What degree in pharmacy did you complete (Check all that apply) 
    □ B.S. 
    □ Pharm. D. 
    □ M. S. 
    □ Other (please specify) ________________________________ 
 
7. What is your position or title? 
    □ Staff pharmacist 
    □ Pharmacist in Charge 
    □ Owner 
    □ Other (please specify) ________________________________ 
 
8. How many prescriptions does your pharmacy fill in a typical week? _____________ 
9. How many full-time equivalent (FTE) pharmacists does your pharmacy employ? 
    □ Part-time equivalent (PTE)  
_____________ 
 
_____________ 
10. How many certified technicians (full and part) are employed at your pharmacy? 
    □ Non-certified technicians (full and part)  
_____________ 
 
_____________ 
11. How many hours is your pharmacy open per week? _____________ 
12. How many employees staff the pharmacy at a give time? _____________ 
13. Would you consider your practice to be in an urban setting or a rural one? _____________ 
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14. Please answer the following questions concerning the physical environment of your pharmacy: 
 
 
 Yes No 
Does your pharmacy have a private counselling area (away from 
pharmacy staff and other patients)? 
  
Does your pharmacy have a semi-private counselling area (away 
from other patients)? 
  
Does your pharmacy have access to online drug information 
resources (I.e. LexiComp, MicroMedex, Epocrates, etc.)? 
  
 
15. Which of the following is the most common payer for prescription drugs in your pharmacy? 
    □ Cash 
    □ Medicaid 
    □ Other third-party payer 
16. Which of the following services do you offer in your pharmacy (Check all that apply)? 
    □ Immunizations 
    □ Durable Medical Equipment 
    □ Disease State Management 
    □ Medication Therapy Management 
    □ Compounding 
    □ Health Screenings 
    □ Others__________________________________________________ 
Section II – Community Pharmacy Research Networks: CPRNs are groups of pharmacists working together to 
answer community-based health community-based health care questions and translate research findings into 
practice. 
17. Please indicate your level of agreement with the following statement: Community pharmacists play an 
important role in healthcare-related research. 
    □ Strongly agree 
    □ Agree 
    □ Disagree 
    □ Strongly disagree 
18. How do you believe that participation in a Community Pharmacy Research Network would affect the 
quality of care that patients receive at your pharmacy? 
    □ Greatly improve quality of care 
    □ Somewhat improve quality of care 
    □ No impact on quality of care 
    □ Somewhat worsen quality of care 
    □ Greatly worsen quality of care 
19. How do you believe that participation in a Community Pharmacy Research Network would affect your 
patient’s perception of the care that they receive at your pharmacy? 
    □ Greatly improve the perception of care 
    □ Somewhat improve the perception of care 
    □ No impact on the perception of care 
    □ Somewhat worsen the perception of care 
    □ Greatly worsen the perception of care 
20. How would participation in a Community Pharmacy Research Network affect your job satisfaction? 
    □ Major increase in job satisfaction 
    □ Slight increase in job satisfaction 
    □ No impact on job satisfaction 
    □ Slight decrease in job satisfaction 
    □ Major decrease in job satisfaction 
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21. Which of the following do you believe is a reasonable compensation for a pharmacist’s participation in a 
Community Pharmacy Research Network? 
    □ $0 
    □ $10-$25 per hour 
    □ $26-$40 per hour 
    □ $41-$55 per hour 
    □ >$55 per hour 
22. How important would the following be in influencing your decision to participate in a Community 
Pharmacy Research Network? 
 Having a research assistant provided by the network who will assist you in conducting 
research projects 
             □ Very important 
             □ Important 
             □ Somewhat important 
             □ Not important 
 
 Having another pharmacist relieve you from all other pharmacy activities while conducting 
research projects 
             □ Very important 
             □ Important 
             □ Somewhat important 
             □ Not important 
 
 Having the opportunity to be a preceptor for student pharmacists who would be able to assist 
in conducting research projects 
             □ Very important 
             □ Important 
             □ Somewhat important 
             □ Not important 
 
 Having an opportunity to suggest future research topics for consideration within the 
Community Pharmacy Research Network  
             □ Very important 
             □ Important 
             □ Somewhat important 
             □ Not important 
23. If the Community Pharmacist Research Network provided a research assistant to assist in data 
collection, what do you believe would be your level of interest in participation in a Community Pharmacy 
Research Network? 
    □ Very interested 
    □ Interested 
    □ Not very interested 
    □ Definitely not interested 
24. If the Community Pharmacy Research Network provided funds to pay for an additional pharmacist to 
conduct research projects, what do you believe would be your level of interest in participation in a 
Community Pharmacy Research Network? 
    □ Very interested 
    □ Interested 
    □ Not very interested 
    □ Definitely not interested 
25. Rank the following order of importance (1=most important; 4=least important) in deciding whether or not 
you would participate in a Community Pharmacy Research Network 
 ____Having the opportunity to participate in a study that may be published in a scholarly journal such 
as the Journal of the American Pharmacists Association 
 
____Having the opportunity to impact the practice of community pharmacy and improve your 
independent pharmacy 
 
____Having the opportunity to present the results of a Community Pharmacy Research Network study 
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at regional or national meetings 
 
____Financial compensation for participation in a Community Pharmacy Research Network 
26. Rank the following in order of importance (1=most important; 3=least important) to improving your 
satisfaction with your practice setting: 
____Solving clinical unknowns 
 
____Solving workflow issues 
 
____Solving insurance issues 
27. Would you be willing to work with elder adults on research to improve their prescription drug safety? 
Yes____    No____ 
 
a) If yes, what degree of assistance would you be willing to provide. (Check all that apply) 
____ Display a flyer 
____ Distribute a flyer to patients 
____ Patient screening 
____ Patient referral into intervention program 
____ Host a kiosk containing a computerized program for patient self-screening, self-referral, 
and/or brief computerized intervention delivery 
____ Directly deliver a <1 minute brief-intervention 
____ Directly deliver a <5 minute brief-intervention 
               ____ Directly deliver a <10 minute brief-intervention 
28. Would you be willing to help raise elder adult awareness about the risks of alcohol consumption and 
prescription drug safety? 
Yes____    No____ 
29. Which of the following best represents your level of interest in participating in a Community Pharmacy 
Research Network? 
    □ Very interested 
    □ Interested 
    □ Not very interested 
    □ Definitely not interested 
    □ I do not know enough about Community Pharmacy Research Networks to respond to this 
30. How many hours per week would you be willing to devote to participation in a Community Pharmacy 
Research Network? 
_______________Hours per week 
31. How many hours per week would you be able to devote to participation in a Community Pharmacy 
Research Network? 
_______________Hours per week 
32. What is the biggest limitation that would keep you from participating in a Community Pharmacy 
Research Network? 
33. Are you interested in learning more about opportunities to participate in a Community Pharmacy 
Research Network in the future? 
Yes____    No____ 
Figure 17. Community Pharmacy Research Network Survey (adapted from (30)). 
 
 
FTE: full-time equivalent PTE: Part-time equivalent  
 Clinical Research in Community Pharmacies – Trying to find a way  
 
51 
To apply this survey to the Portuguese reality, some issues should be taken into 
consideration. It is necessary to translate, adapt and validate this survey to the 
Portuguese community pharmacy population. The methodology for this task is proposed 
below.  
The translation of this questionnaire into Portuguese (of Portugal) language would involve 
running two panels: a bilingual translation panel and a lay translation panel aiming to 
produce the most appropriate version of the survey in Portugal’s Portuguese (78, 79). 
The objective of the bilingual translation panel is to produce the first translation of the 
survey. This panel would contain five or six individuals, who are fluent in both English and 
Portuguese, with the Portuguese as their first or primary language. There is no need to be 
medically trained or professional translator. As far as possible, there should be 
approximately equal numbers of men and women and they should vary in age. The ideal 
method of running this panel is to use a computer attached to an overhead projector. The 
original survey is projected and one person will type in the Portuguese language under the 
English original. All members of the panel are then able to see the source item together 
with alternative translations. The group can then decide which one (or more) of the 
translations should be retained for consideration by the lay panel. The same method 
should be used to produce the questionnaire instructions in the Portuguese language (78, 
79). 
A lay panel would be required in order to ensure that the level of language used is 
appropriate for those who will then complete the survey. Since bilinguals often use 
somewhat different words or phrases from lay people, it is important to have the survey 
translated by a lay panel. This panel would only consider the translation produced by the 
bilingual panel. The original version would not be available to them. However, the group 
leader (the person who attended the bilingual panel) would ensure that the final version 
produced by the lay panel has conceptual equivalence to the original version. The lay 
panel should be able to see projected the Portuguese language item (or alternatives) and 
they should discuss the wording of the items and decide whether these are acceptable or 
if changes are required to improve clarity and immediacy (78, 79). 
It is helpful if a range of ages is represented in this group to ensure that the final measure 
is acceptable to all age groups. If the panel is "too young", modern phrases might be 
included that are less well understood by older people. If the panel is "too old" the wording 
may appear stilted or old fashioned. At the very least, there should be at least one 
younger and one older (post-retirement) participant. There should be approximately equal 
number of men and women present (78, 79). 
To validate the obtained survey a sample of community pharmacies would be required to 
test the new language version. The application of the survey should be made on two 
occasions, two weeks apart, and should be standard in both time points.  
Once there is a validated translation of the mentioned survey, it should be applied to 
almost all Portuguese community pharmacies. According to the obtained results, it would 
be possible to assess the interest of Portuguese community pharmacies in participating in 
clinical research, giving us the baseline to all the posterior work on this issue. 
  
 
 
 Clinical Research in Community Pharmacies – Trying to find a way  
 
53 
7. DISCUSSION  
 
 
Many pharmacists feel disappointed with their non-challenging dispensing role because 
they thought that closer involvement with the population would make their work more 
pleasing. Many pharmacists think their skills are being under-used, feeling like “over-
qualified distributors of medicines” and needing for new challenges (2). 
In regard of clinical trials, studies have shown that pharmacists would be very willing to 
provide trial information to interested patients. Likewise, customers with better 
relationships with pharmacists were more willing to accept information about clinical trials. 
Nevertheless, only 25% of pharmacists were prepared to discuss this with a pharmacy 
customer (45, 48).  
The reason more often referred by community pharmacies as the reason for not 
participating in a study was time constraints associated with the busy practice 
environment in many community pharmacies. Lack of time is always the reason referred 
by who decline to participate in a study (47, 39, 38, 19, 46). 
There are some strategies that might be used to enhance study-site recruitment (47):  
 Endorsement and initial contact by the state professional association partners; 
 Rapid recruitment contact by pharmacist members of the study team who are 
supported by study staff dedicated to the consent process; 
 Modest financial incentives for participating pharmacy personnel. 
The environment in which a community pharmacy is inserted and their closeness to 
primary care enables it to be part of several clinical studies that seek to provide 
information and answer the clinical conditions most frequently found in the community. 
In Portugal, it can be seen that the current paradigm of community pharmacy is 
mandatorily conducting to the development of new skills and services. The involvement of 
Portuguese community pharmacies in clinical research may be a path to strengthen the 
role of pharmacies in the community, the National Health Service and the pharmaceutical 
industry itself. 
It can be noted that several stakeholders are needed to perform clinical research. In this 
way, it would be good to increase the participation of Portugal in clinical trials in order to 
generate sustained new jobs. Nowadays, even more than at any other time, this would 
have a positive impact in Portugal.  Although more prescriptions are in the pipeline than 
ever before, community pharmacists face today unprecedented challenges. In the last two 
decades, prescription margins have been cut by more than 50%, and competition from 
mail order and large retail chains has intensified (45). There are several factors that make 
pharmacists more receptive to new ways for generating revenue, and their deepening 
relationships with patients make them an attractive clinical trial recruitment channel (45). 
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It was shown that clinical trials can benefit from pharmacists’ involvement.  A study 
examined this impact through a survey held 3 months after the display of in-store clinical 
trial educational materials and pharmacist outreach activities. It was found that 1 in 7 
respondents spoke to their pharmacist or the pharmacy staff about clinical trials. 82% of 
pharmacists reported speaking with patients about clinical trials, and 78% thought that 
patients were interested in learning about clinical research.  47% of patient respondents 
were interested in participating in a clinical trial, and 48% were likely to recommend that a 
friend or family member look for ways to participate in clinical research. Nearly 4% of 
patient respondents chose to participate in a clinical research study after seeing 
educational materials in their pharmacies (45). 
Thus, each time a pharmacist talks to a patient it is an opportunity for clinical trial 
education. The patient-pharmacist relationship enables community pharmacists to 
differentiate themselves from their competitors and give insights into various determinant 
factors whether a patient is a good candidate for a clinical trial (45). 
This was showed on the McKesson StudyLink Program, selected by a sponsor to identify, 
recruit, pre-screen, enrol and compensate newly diagnosed migraine patients who were 
eligible only if they were new to taking the study medication and had recently taken this 
medication for the first time. The challenge of this issue relates to the fact that it refers to 
newly diagnosed patients. It is easy to use prescription data to identify large number of 
patients using the study medication, but not so easy to find those who were newly 
diagnosed (45). 
Community pharmacies perceive that they are able to provide routine and specialized 
services that benefit the community. They are entities having staff with suitable knowledge 
and capabilities to contribute on clinical trials conduction. Moreover, cooperation from 
health professional, peer support, and funding are important facilitators for the 
development of new services (23). To perform clinical research in a community pharmacy 
setting it is important that subjects take their prescriptions always in the same trial 
pharmacy. In fact, this is similar from everyday practice for many people, as they tend to 
choose always the same pharmacy. Comprehensibly, temporary residents such as 
tourists and students would have to be excluded (13). 
A study conducted in Portugal by PriceWaterHouseCoopers showed that clinical research 
activities would be of great impact for Portugal social and economical development. It was 
shown that clinical research would allow clinical trial participants an early access to new 
drugs and therapeutics before its marketing. In the meantime, physicians participating in 
clinical research would benefit of their training and continuous development, as well as 
medical practice would benefit with the rigorousness imposed by the clinical research 
methodology. The improvement of the clinical research approach would benefit the 
scientific development of the country and the creation of centres of excellence (10). 
In the meantime, and of great importance in the current Portuguese situation, clinical 
research would reduce public expenses, since the treatment of patients participating in 
clinical trials are funded by the respective sponsor and the treatment prescribed and 
supported by the National Health Service is replaced. 
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At the same time, this would benefit the creation of new qualified jobs, since there is a 
need to reinforce human resources in clinical trial sites, pharmaceutical companies and 
CROs.  
In this way, it would greatly benefit the Government in tax revenues, improvement of the 
sector trade balance with important stimulating role on the value chain.  
This work intended to be an approach and verification of what is happening in other 
countries. As can be seen, much work has been done in this field in recent years. 
Therefore, an increased intervention of community pharmacists on clinical research is 
expected to be of relevant importance for the Portuguese Healthcare System. More 
studies shall be done to create a workable system. 
The approval of the new Law of Clinical Research (Law No. 21/2014 of 16th April), is 
positioned as an incentive to the involvement of other entities, beyond hospitals, in 
conducting clinical research in Portugal. The Portuguese community pharmacies may well 
be included in this paradigm in several ways: 
 Participation in the experimental drug circuit in clinical trials in health units; 
 Facilitating Clinical Trials in Portugal, participating in education of the population 
about this issue. 
 Conducting clinical studies in pharmacy itself, either through observational studies, 
or through interventional studies (with use of OTC drugs, for example).  
In our view, the first step would be to raise consciousness among Portuguese community 
pharmacists to this reality, so that when establishing the system, there are capable, 
trained and sensitized professionals to this new strand of their work.  
There are several studies that may be applicable to Portugal. First of all, it is important to 
apply a questionnaire to a representative sample of Portuguese community pharmacists in 
order to identify their interest to take part in clinical research. Carr et al. published the 
questionnaire used in their study (cf. Figure 17), which may be adapted for use in Portugal 
(30). In a subsequent phase, other studies may also be of great interest to be adapted to 
Portuguese reality. This is the case of the survey of Saini et al. on factors influencing 
Australian community pharmacists’ willingness to participate in research projects and of 
Peterson et al. on attitudes of Australian pharmacists towards practice-based research 
(39, 34). There are several networks that may be used to spread this survey: it could be 
done through Ordem dos Farmacêuticos (OF) or Associação Nacional de Farmácias 
(ANF – National Association of Pharmacies), since it represents most of the Portuguese 
pharmacies.  
First it is suggested to use the questionnaire of Carr et al., since it would fit for purpose. 
As stated, this questionnaire would need to be adapted for Portugal. In this way, it is 
necessary to translate and validate this questionnaire into Portuguese. 
Figure 18 shows the parameters of a Strengths, Weaknesses, Opportunities, and Threats 
(SWOT) analysis applied to our suggestion. A SWOT analysis is an established method 
for assisting the formulation of strategy analysis. (80) Strengths and weaknesses refer to 
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attributes with an internal origin and Opportunities and Threats refer to attributes of the 
environmental. As one could estimate, Strengths and Opportunities refer to something 
helpful to achieve the objective and Weaknesses and Threats refer to something harmful 
to achieve the objective. 
 
 
Figure 18. SWOT analysis of Carr et al’s questionnaire application in Portugal 
In this case, the possibility to evaluate the perception and acceptability of the Portuguese 
community pharmacies regarding clinical research and the ease of access to a broad 
network of pharmacies, are positioned as Strengths of the application of this 
questionnaire. In the same way, the need to be able to encourage all pharmacies to 
participate and that pharmacies are receptive to changing mindset in a time of economic 
constraints makes them the anticipated Weaknesses of this questionnaire. On the other 
hand, it can be found that the need for change felt in the pharmaceutical sector and the 
Portuguese community pharmacies in particular, as well as the New Portuguese 
Legislation on Clinical Research (Law No. 21/2014) that leads a space to conducting 
clinical research in other areas than just the hospital, appear as Opportunities in our case 
study. Research in Pharmacy is covered by this new law and the participation of 
pharmacists in clinical trials in primary health units are also one of opportunities achieving 
this investigation would foster. On the other hand, the period of economic crisis that 
Portugal is facing and lack of response by pharmacists seem to be the major Threats that 
could be found. 
It was also an objective of the project to find what has been done in Portugal on this 
matter, but information on clinical trials performed within a community pharmacy setting is 
scarce. Nevertheless, it was noted that some observational studies are already practice in 
community pharmacies. 
Strengths 
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•Easy access to a 
broad network of 
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•Need of 
enforcement 
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changing 
Opportunities 
•Need for a change 
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Portuguese community pharmacies and pharmacists mindset would only change if some 
proposals are offered. This work and the application of the questionnaire would awake 
community pharmacies to this reality which often might not occur, since it differs to 
nowadays common daily practice.  
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8. CONCLUSION  
 
 
In the last years, community pharmacists moved from the traditional product supply role to 
a more interventional one in the community. 
Nevertheless, many pharmacists continued to feel their capacities as underused. 
Pharmacists, by their basic training, have an enormous capacity for intervention in various 
fields on Health. Clinical research is one of them.  
For pharmacists, determining whether to participate in a clinical trial boils down to two 
simple questions: Is this the right thing to do for my patients? Will this be worth my time? 
The answer to the latter will depend not only on the compensation received, but on the 
relationship-building opportunities that such programs can offer. Those pharmacists who 
recognize that these relationships can be a differentiating competitive advantage would be 
more likely to participate. 
The high level of user satisfaction with the pharmacy is a mean for facilitating the 
recruitment/advice on clinical trials in community pharmacy. Conducting community 
pharmacy studies represents a range of difficulties. However, it is possible to design a 
pharmacy based trial in accordance with GCP Guidelines.  
This study showed the international reality on this issue, in order to be the basis of further 
studies on this matter, in such a way to be applied to Portugal.  
Nowadays, the Primary Healthcare Setting is getting more and more importance in 
Portugal. The Primary Health Care reform has great importance in the landscape of 
Health in Portugal. The starting point for this reform was the result of a low level of 
satisfaction of all stakeholders. This reform involves a set of supporting principles as 
decentralization, self-organization and responsibility for results, and contributed 
significantly to increase access to health care. In Europe, the need of greater investment 
in primary healthcare to enable health systems to fulfil all their potential to the benefit of 
patients has been considered. It can be noticed that the investment not only has to do with 
human resources and infrastructure, but also with education, research, training, and 
continuous quality improvement.  
On the other hand, it is recognised that data about patients’ use of medicines in normal 
clinical practice – Real World Data – is ever more important in decisions affecting patients’ 
access to medicines. Studies that demonstrate the value of medicines and aid developing 
new practices in the healthcare system provide many benefits by maximising the use of 
resources, benefiting patients and their compliance with medicines’ administration.  
The conduction of randomised controlled trials is very expensive. In the other hand, the 
lower costs and simplicity of real world data studies is an advantage that has powered the 
relevance of such studies. It is estimated that the presentation of real world data would 
become even more important in decisions affecting access to medicines. The collection 
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and use of this kind of data can enable all parties to achieve their objectives and, 
ultimately, to maximise patients’ health gains. 
It has been shown that other countries have woken up to the need to include and integrate 
community pharmacies in this area. Recent reforms of the health system in Portugal, 
including the publication of the Portuguese Law on Clinical Research (Law No. 21/2014, 
of 16th April) demonstrate the intention to improve this kind of research on healthcare 
outcomes for patients. Portugal has many advantages in positioning itself as interesting 
on the development of clinical research. It would be helpful if we are aware that this 
paradigm shift is necessary and good. 
This work intended to be guidance and a push for clinical trials performance in Portuguese 
community pharmacies setting. In order to increase pharmacist’s interest in research and 
facilitate their involvement, there is a need to fully investigate the barriers and facilitators 
to this new role. It is suggested the application of the questionnaire applied by Carr et al. 
to assess community pharmacists’ opinion on this matter.  
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